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UNDERSTANDING EXPOSURE TO PHARMACOGENETICALLY ACTIONABLE 
OPIOIDS IN PRIMARY CARE 
 Pharmacogenetic testing has the potential to improve pain management through 
addressing wide interindividual variations in responses to pharmacogenetically 
actionable opioids, ultimately decreasing costly adverse drug effects and improving 
responses to these medications. A recent review of pharmacogenomics in the nursing 
literature highlighted the need for nurses to more fully embrace the burgeoning field of 
pharmacogenomics in nursing research, clinical practice, and education. Despite the 
promise of pharmacogenetic testing, significant challenges exist for evaluating outcomes 
related to its implementation, including oversimplification of medication exposure, the 
complexity of patients’ clinical profiles, and the characteristics of healthcare contexts in 
which medications are prescribed. A better understanding of these challenges could 
enhance the assessment and documentation of the benefits of pharmacogenetic testing 
in guiding opioid therapies. This dissertation is intended to address the challenges of 
evaluating outcomes of pharmacogenetic testing implementation and the need for 
nurses to lead pharmacogenomic-related research. The dissertation purpose was to 
advance the sciences of nursing, pain management, and pharmacogenomics through 
the development of a typology of common patterns of medication exposure to known 
pharmacogenetically actionable opioids (codeine & tramadol). A qualitative, person-
oriented approach was used to retrospectively analyze six months of electronic health 
record and pharmacogenotype data in 30 underserved adult patients. An overarching 
typology with eight groups of patients that had one of five opioid prescription patterns 
(singular, episodic, switching, sustained, or multiplex) and one of three types of medical 
vi 
emphasis of care (pain, comorbidities, or both) were identified. This typology consisted 
of a description of multiple common patterns that compare and contrast salient factors of 
exposure and the emphasis of why individuals were seeking care. Furthermore, in an 
aggregate descriptive analysis evaluating key clinical profile factors, these patients had 
complex medical histories, extensive healthcare utilization, and experienced significant 
polypharmacy. These findings can aid in addressing challenges related to the 
implementation of pharmacogenetic testing in clinical practice and point to ways in which 
nurses can take the lead in pharmacogenomics research. Findings also provide a 
foundation for future studies aimed at developing medication exposure measures to 
capture its dynamic nature and identifying and tailoring interventions in this population.  
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CHAPTER 1 
 This chapter introduces the dissertation topic of the development of a typology of 
common patterns of exposure to known pharmacogenetically actionable opioid 
medications (codeine and tramadol) in a primary care setting. The chapter provides a 
discussion of the significance of the topic, identifies the purpose of the dissertation, and 
outlines the study methods.  
Background & Significance 
Significance of Pain 
 Pain is a prevalent, costly, and inadequately managed health problem. The most 
common reason Americans seek healthcare is pain,1 “an unpleasant sensory and 
emotional experience associated with actual or potential tissue damage or described in 
such terms.”2 Acute pain is a protective sensation alerting an individual to a possible or 
actual tissue injury lasting a short period of time, whereas chronic pain is pain or 
discomfort lasting long beyond its useful and protective function.3, 4 Chronic pain affects 
100 million people in the United States and produces annual costs of $635 billion, 
making it the most prevalent and costly health condition.3 Additionally, one in four, or 
76.2 million, Americans have experienced pain lasting longer than 24 hours.1, 5 
Approximately 50% of individuals with acute or chronic non-cancer pain experience 
inadequate management of their pain.4, 6 Inadequate pain management leads to an array 
of negative consequences such as development of chronic pain syndromes, decreased 
functional status and health-related quality of life, disability, increased demands on the 
health system, and economic burdens including increased healthcare expenditures and 
disability compensation.3, 4, 7   
Pain & Pharmacogenomics 
 It is crucial for pain management science to incorporate the rapidly evolving field 
of pharmacogenomics, the study of individual genetic variations associated with drug 
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metabolism and response.8 One reason for inadequately managed acute or chronic pain 
is genetic variation.8-11 Genetics can influence the pharmacodynamics and 
pharmacokinetic disposition of opioids.12 Genetic variations are associated with adverse 
drug effects and poor drug response, ultimately leading to poor patient outcomes.11, 13 
 Opioid medications have been a mainstay for the treatment of pain for years. 
Unfortunately, there are wide individual variations in analgesic efficacy and adverse drug 
effects to commonly prescribed opioids that are known to be pharmacogenetically 
actionable, such as codeine and tramadol which have evidence based guidelines to 
guide prescribing decisions based on pharmacogenetic test results.10 Approximately 
10% of Caucasians receive inadequate or no analgesia from codeine due to genetic 
variations in the CYP2D6 enzyme metabolizing the drug to its active form, morphine.14-16 
Furthermore, 3% of Caucasians ultra-rapidly metabolize codeine due to genetics, which 
increases the incidence of drug-related adverse events and reactions.17 Like codeine, 
tramadol is metabolized by the same CYP2D6 enzyme and people have varied clinical 
responses due to genetic variations.18, 19  
Implementing Pharmacogenetic Testing in Clinical Practice 
 International and national guidelines for medication dosing adjustments based on 
pharmacogenetic test results exist,20 but have not been widely implemented in 
practice.21-24 It is broadly believed that making dose and medication adjustments based 
on pharmacogenetic testing can improve clinical and economic outcomes through 
decreasing costly adverse drug reactions and improving medication response.8, 25-28 As 
pharmacogenetic testing becomes more integrated within routine clinical practice, it will 
be necessary to further evaluate its impact on clinical and economic outcomes that are 
related to the use of pharmacogenetically actionable opioids.29, 30 However, there have 
been numerous methodological challenges noted when evaluating the effects of 
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pharmacogenetic testing, including medication exposure measurement errors and the 
complexity of patients, clinical context, and diseases being treated.28, 31, 32   
 Medication exposure. Medication exposure can be defined as the condition of 
being subjected to a medication. Medication exposure includes multiple factors such as 
the medication and dose prescribed, the medication regimen, and changes in the 
regimen over time.33 Although there is no standardized measure for medication 
exposure, medication exposure is dynamic and can change from day to day or month to 
month. Consequently, an exposure measure should capture medication use beyond a 
single event.34  
 In general, studies and meta-analyses evaluating the efficacy or effectiveness of 
pharmacogenetic testing have oversimplified medication exposure and fail to capture its 
dynamic and heterogeneous state in relation to actual or predicted outcomes.26, 35, 36 To 
date, only a handful of data-based articles have reported on exposure to known 
pharmacogenetically actionable medications, including opioids.26-28, 36 These studies 
have counted the number of patients taking such medications. Among 52,942 primary 
care patients, for example, 65% of patients received a prescription for at least one 
pharmacogenetically actionable medication and at least 23% were prescribed three or 
more during a 5-year period.36 More than 10% of these patients received a prescription 
for tramadol or codeine.36 In another study of 1,013 primary care patients at high risk for 
starting statin therapy, 75% were prescribed tramadol and 48% were prescribed codeine 
at least once during a 20-year period.23 Other studies have evaluated characteristics of 
opioid exposure (e.g., dose37-41; co-administered analgesics and other medications39, 41, 
42; dosing schedule38; and whether a medication was discontinued43); however, these 
studies have all used traditional variable-oriented approaches to data analysis. Variable-
oriented approaches use the variable (e.g., total number of patients taking opioid 
medications) as the main conceptual and analytic unit, resulting in a failure to capture 
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the holistic view, complexity, and the interplay among variables (factors) of medication 
exposure at the person level.44  
 Contextual factors. Understanding contextual influences, or the factors that are 
not directly part of existing evidence-based pharmacogenetic guidelines, can increase 
certainty of the relationship between outcomes and the implementation of 
pharmacogenetic testing.45 Unfortunately, clinical guidelines that are used as a 
foundation for practice changes are limited in relation to the context in which medications 
are prescribed.46 Contextual factors, such as a patient’s clinical profile, have the ability to 
influence medication exposure to pharmacogenetically actionable opioids and confound 
outcomes being evaluated to determine benefits of the implementation of 
pharmacogenetic testing.28, 31, 32 Currently, studies are limited in exploring or including 
contextual influences that could impact outcomes related to the use of pharmacogenetic 
testing to guide opioid therapies in clinical practice. 
Using A Person-oriented Approach to Understand of Medication Exposure 
 A person-oriented approach (consisting of 2 components – person-oriented 
theory and person-oriented methods) is ideal for more completely understanding the 
realities of exposure to pharmacogenetically actionable opioids in which salient factors 
and needs occurring at the level of the whole person can be captured through the 
development of typologies.44, 47, 48 Person-oriented approaches view the individual as an 
organized whole, functioning and developing as a totality, with the totality being formed 
by all factors involved.44 For example, knowing a patient is taking tramadol (measured 
either as no/yes tramadol or as taking no vs. one medication known to be 
pharmacogenetically actionable) fails to reflect the true regimen complexity. A 
prescription for tramadol might be written as 25 mg daily with instructions to increase by 
25 mg every three days until a final dose of 100 mg is reached. Additionally, individuals 
experiencing pain often seek new opioid prescriptions or modifications to medication 
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regimens from multiple providers49; thus, identifying where the opioid prescription 
originated and where adjustments to opioid regimens are made is important (e.g., 
emergency department, specialty clinic). Therefore, to truly reflect the complexity of the 
regimen and to classify the pattern of exposure appropriately, it is necessary to 
understand a wide array of information such as complete prescription details (e.g., 
whether the medication dose was increased or reduced, whether it was discontinued 
and another started, prescriber), clinical responses (e.g., adverse events), and health 
care utilization (e.g., where modifications to regimen were made; need for clinic, 
hospital, emergency department visits). In a person-oriented approach, typologies are 
developed to organize these factors47, 50 to understand patterns and commonalities.50  
 This approach can be beneficial to clinicians, researchers, and policy makers 
since they are continuously challenged to address the health needs of individuals and 
populations without a comprehensive picture of the relevant factors.51 Developing a 
typology will provide important baseline information to more comprehensively 
understand factors most salient in determining how medication exposure unfolds over 
time as well as meaningful subgroups of individuals that share common patterns of 
medication exposure.  
Topical Fit to National Priorities 
 Understanding medication exposure to pharmacogenetically actionable opioids 
meets national nursing research priorities. The National Institute of Nursing Research’s 
Strategic Plan emphasizes the need to explore multiple factors, including health 
determinants such as psychological, physiological, genomic, and environmental factors, 
that influence health promotion and self-management of acute and chronic conditions 
such as pain.52 Because medication management is a significant component of self-
management, identifying the multidimensional and complex patterns of medication 
exposure is a necessary step to inform strategies to improve health promoting and self-
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management behaviors.52-54 Thus nurse scientists are in a unique position to provide a 
holistic, person-oriented evaluation of medication exposure of individuals receiving 
pharmacogenetically actionable medications. This will aid in identifying factors most 
salient in determining how exposure unfolds over time and understanding the health 
needs of individuals seen in primary care who experience acute or chronic pain. 
 This research also addresses key research issues identified in the Summary 
Report of the NIH-sponsored 2014 Pathways to Prevention Workshop: The Role of 
Opioids in the Treatment of Chronic Pain. This Report highlighted the need to more 
comprehensively understand drug-related, genetic, and other patient-related factors 
affecting the use of opioids in managing pain.55 There is a paucity of research in this 
area. Therefore, detecting common patterns of exposure to pharmacogenetically 
actionable opioid medications and related factors will contribute to the advancement of 
the interdisciplinary sciences of nursing, pain management, and pharmacogenomics 
more broadly. 
Aims of the Dissertation 
The overarching goal of this dissertation is to advance the sciences of nursing, 
pain management, and pharmacogenomics through developing a typology describing 
common patterns of exposure to known pharmacogenetically actionable opioid 
medications (tramadol and codeine). To achieve this goal, three different yet related 
manuscripts were developed and are presented as Chapters 2, 3, and 4 within this 
dissertation.  
Chapter 2 consists of a comprehensive review of the state of the science of 
pharmacogenomics as reflected in the nursing literature, with specific aims to critically 
examine: (1) the concepts of pharmacogenomics and pharmacogenetics; (2) 
pharmacogenomic and pharmacogenetic clinical practice applications; and (3) nursing’s 
responsibilities in pharmacogenomics and pharmacogenetics. The primary purpose of 
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Chapter 3 was to employ a qualitative person-oriented approach to develop a typology 
that identified meaningful subgroups that shared common patterns of medication 
exposure within a sample of patients newly prescribed a pharmacogenetically actionable 
opioid in primary care clinics part of a safety-net health system. And finally, the goal of 
Chapter 4 was to describe the context in which pharmacogenetically actionable opioids 
were prescribed, including patients’ comorbidities, healthcare utilization, and 
polypharmacy, in a large safety-net health system.  
 In the following sections of this chapter, the theoretical and methodological basis 
and approaches of obtaining data and conducting analyses to develop the typology of 
medication exposure to pharmacogenetically actionable opioids are discussed.  
Approach 
Theoretical & Methodological Basis  
 A person-oriented approach was used in lieu of a more traditional variable-
oriented approach. In a person-oriented approach, the individual is the analytic unit and 
patterns of salient factors related to the phenomenon of interest are used to divide a 
heterogeneous sample into subgroups that share common characteristics.44, 56 In a 
variable-oriented approach, variables that capture theoretical constructs are the primary 
analytic units and relationships among these variables are investigated. Although the 
strengths of variable-oriented approaches are well known and include the power of 
inferential statistics and model testing to yield causal inferences, only analyzing pairwise 
relationships among variables and ignoring patterns at the person level can fail to reflect 
the complex ways variables are inter-related within subgroups.57  
 The person-oriented approach has two components; theory and methods.48 
Person-oriented theory, rooted in develomental psychology, consists of the following 
tenets: (1) The structure and dynamics of behavior are partly specific to individuals; (2) 
the phenomenon being studied is complex and is conceptualized as involving many 
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factors interacting at various levels that may be mutually related in a complicated 
manner; (3) there is lawfulness and structure to intra-individual constancy and change as 
well as inter-individual differences in constancy and change; (4) processes develop in a 
lawful way and can be described as patterns; (5) meaning of the involved factors is 
defined by the interactions among these factors; and (6) some patterns occur more 
frequently whereas others occur less frequently than expected.44, 48 Person-oriented 
research methods based on person-oriented theory focus on individual cases or 
homogeneous groups. Though many data analytic techniques based on a person-
oriented theory are quantitative in nature (e.g., configural frequency analysis), qualitative 
techniques, such as cross-case analysis,58 provide another way of identifying and 
describing homogeneous subgroups within a larger population.  
 Factors to include in the person-oriented analysis were derived from the literature 
(see Figure 1-1). Patient factors are known to influence opioid prescribing and use 
including demographics59-67, past medical history68-75, and pharmacogenetic 
genotyping.76, 77 Medication information important to determining exposure includes 
opioid dose, frequency, and duration over time34, 37-43; co-prescribed medications39, 41, 42; 
and prescriber.49, 62, 78 Clinical response to opioids is assessed in terms of pain 
intensity68-70, 72, 74, 75, 79, 80 and adverse events68-70, 74, 75, 80 and these can impact healthcare 
utilization (clinic visits, emergency department visits, hospital admission).49, 55, 79, 81  
Design  
 This was a retrospective, 6-month, longitudinal analysis of de-identified, 
electronic health records and DNA from banked blood samples. The electronic health 
records were housed and maintained at the Regenstrief Institute, and those records are 
linked to blood samples within the Indiana Biobank.  
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Sample 
 Inclusion criteria and rationale. Electronic health records were obtained from a 
cohort of patients meeting the following inclusion criteria:  
1) First prescription of record for codeine or tramadol in primary care clinics 
within the past 5 years (1/1/10-12/31/14); 
2) member of the Eskenazi Health’s Health Advantage managed care program; 
3) have a blood sample in the Indiana Biobank; 
4) age 21 or older; and 
5) no documentation of substance abuse in the electronic medical record.  
 Rationale for inclusion criteria. Eskenazi Health’s Health Advantage is a 
managed care program, consisting of more than 52,000 members, providing high-
quality, seamless medical care to low-income and uninsured residents of Indianapolis 
falling at or below 200% of the federal poverty level and not qualifying for any other 
assistance program.82 This population was chosen because the members of Health 
Advantage must seek care at Eskenazi Health affiliated clinics for coverage and all 
health records that are part of this plan, including outpatient pharmacy records, are 
tracked, stored, and accessible through the Regenstrief Institute. Additionally, the 
Regenstrief Institute has the ability to include data from the Indiana Network for Patient 
Care, which captures health records and utilization outside of the Eskenazi Health 
system. The 5-year time frame to identify electronic health records meeting inclusion 
criteria was selected to help limit any external influences (e.g., legislative changes) that 
would change provider prescribing practices affecting medication exposure for the 
included cases. Additionally, codeine and tramadol were chosen because, at the time of 
this study, these are the only opioid medications with actionable pharmacogenetic 
information on FDA drug labels.20 All trade and generic versions of each of the opioids 
will be included. For example, there are two different formulations for tramadol, tramadol 
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hydrochloride and tramadol hydrochloride with acetaminophen.83 Prescriptions for either 
one will be used to identify eligible patients (cases). Electronic health records of 
individuals with known substance abuse will be excluded because this population may 
have distinct patterns of exposure and it will be difficult to ferret out whether their 
exposure to opioids is related to appropriate use for analgesia or for other non-medical 
reasons.51  
 Random selection and sampling. Random selection aided in ensuring the 
sample was representative of the Eskenazi Health primary care population. Eskenazi 
patients, 91% of whom are from Marion County, are broadly representative of 
underserved patients falling within the Index of Medical Underservice scale scores of 0 
to 61.60, where 0 is completely underserved to 100 best served (62 or less qualifies as 
underserved).84 
 The Regenstrief Institute and Indiana Biobank provided a dataset of all electronic 
health records (N = 118) meeting the inclusion criteria. A multiple-case sample was 
produced through randomly selecting a subset of these records using a random 
numbers table. Published recommendations for a multiple-case sample ranges from 10-
30 cases due to the required in-depth analysis as the complexities from larger samples 
would become unwieldy.58 Thus, this study included data from 30 records (cases) for 
analysis.  
Study Procedures  
 Institutional review and approval. Prior to beginning this research the Indiana 
University Human Subjects Office confirmed the study was non-human subjects 
research. Private, identifiable information was not accessible and only de-identified 
electronic health record data and de-identified samples were provided for use in this 
study. Thus, the research did not involve human subjects and IRB review was not 
required.85  
11 
 Data use agreements. A data use agreement was signed with the Regenstrief 
Institute and the Indiana Biobank for the electronic health record data and blood 
samples. Regenstrief’s data analyst abstracted and provided access to the de-identified 
data from electronic health records. The blood samples were released to the clinical 
pharmacology laboratory for pharmacogenetic genotyping. 
 Regenstrief electronic health records data. Six months of electronic health 
record data for each individual were obtained – starting with the first prescription date 
through the following six months. Regenstrief’s clinical data analysts used a process to 
de-identify dates and times through date offsets. Instead of using actual dates/times for 
any particular health record, a random number was assigned and attached to the 
calendar for every associated event. Importantly, the temporal relationship between 
subjects and events was kept in the study data while de-identifying actual dates. For 
example, the number 8 might be randomly selected for a patient seen on January 15th 
and February 15th. The dates in the dataset would appear as January 23rd (15 + 8) and 
February 23rd, thus de-identifying the actual dates while still preserving the temporal 
sequencing of events, including the time lag between encounters.  
 To reflect the person-level factors pertinent to medication exposure, data fields 
(factors) capturing the following were obtained from the electronic health records:  
 Patient characteristics: Demographics of 1) age, 2) gender, 3) race/ethnicity, and 
 4) past medical history (ICD-9 codes).  
 Medication characteristics (every time any prescription is prescribed and 
 filled/refilled [opioids or other medications] in the 6-month time period specified 
 above): 1) medication, 2) dose, 3) dose frequency, 4) route, 5) administration 
 instructions, and 6) prescriber (a de-identified unique number for each 
 prescriber). 
12 
 Clinical response (captured during each healthcare encounter over the 6-month 
 time period): 1) any documented adverse events (based on ICD-9 codes), and 2) 
 pain intensity.  
 Healthcare utilization: 
o Clinic visits (each clinic visit in the 6-month time period): 1) 
name/specialty of clinic, 2) reason for visit (ICD-9 codes), 3) documented 
medication history (including over-the-counter medications), and 4) newly 
prescribed medications. 
o Emergency department visit (each occurrence in the 6-month time 
period): 1) reason for visit, 2) documented medication history, and 3) 
newly prescribed outpatient medications. 
o Hospital admission (each occurrence in the 6-month time period): 1) 
reason for visit, 2) documented past medical history, 3) newly prescribed 
outpatient medications, and 4) length of stay (calculated from admission 
and discharge dates).  
 Indiana Biobank blood samples. Cytochrome P450 2D6 (CYP2D6) 
pharmacogenetic genotype was determined for the 30 cases in this study. The CYP2D6 
gene is highly polymorphic, therefore, we genotyped common variants that influence 
both codeine and tramadol drug disposition and response.46 Samples of extracted DNA 
in the amount of 350 ng/sample and a concentration of 10 ng/µl were released to the 
clinical pharmacology laboratory for storage and analysis. The extracted DNA was 
further diluted to a final concentration of 5.8 ng/µl. Using Taqman Genotyping Assays 
(Applied Biosystems, Inc.) following the manufacturer’s instructions and QuantStudio 
(Thermo Fisher Scientific, Inc., Grand Island, NY), genotyping was performed for the 
CYP2D6 alleles *2, *3, *4, *5, *6, *9, *10, *17, *29, and *41. These star alleles were 
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chosen because of their frequencies in Caucasian and African populations and their 
descendants.86 Quality controls were run for each sample batch and repeated measures 
were conducted on 20% of samples for further validation. Based on the genotype 
results, the CYP2D6 activity score was determined for each case.46  
Analysis 
Data Management 
 Data were maintained on a secure data server in a limited access folder meeting 
standards for storing research-related electronic, protected health information regulated 
by the Health Insurance Portability and Accountability Act of 1996. There was no risk for 
loss of confidentiality since all data are de-identified.  
Data Analysis 
 Sample characteristics were described using descriptive statistics (e.g., means, 
standard deviations, frequencies, and percentages) using SPSSTM 23.0 (IBM, Armonk, 
NY). The remaining data analysis was conducted in three iterative steps of 1) data 
condensation, 2) data display (creating matrices), and 3) drawing and verifying 
conclusions.58 Data analysis was interactive with assistance and verification from 
dissertation co-chairs.  
 Using each of the 30 patients with all corresponding data fields (factors) as a 
case, a within-case analysis as described by Miles et al.58 was completed. The goal of a 
within-case analysis is to “describe, understand, and explain what has happened in a 
single, bounded case (p. 100).”58 To complete this, data was condensed (a process of 
selecting, simplifying, abstracting, and transforming the data into an interpretable 
format58) and organized in a case-by-time (time-ordered) meta-matrix in which patient 
characteristics (age, gender, race/ethnicity, CYP2D6 activity score) were on the vertical 
axis and all other factors (medication characteristics, clinical responses, healthcare 
utilization) were organized by month on the horizontal axis. The case-by-time matrix 
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allowed for development of an in-depth (narrative) description of each case posing which 
factors seem to be most salient in determining how opioid exposure unfolds over time.  
 In typology construction, the phenomena should be understood and explained 
with meaningful relationships derived from empirically founded groups or clusters of 
cases.50 Using the narrative data in the case-by-time meta-matrix from the within-case 
analysis, cross-case analytic procedures were applied.58 Cross-case analysis seeks to 
determine whether multiple cases cluster into groups sharing certain patterns or 
configurations providing the ability to deepen the understanding and explanation of 
similarities and differences across multiple cases.58 The cases were examined for 
repeating patterns of factors of exposure to the opioids and cases that share patterns 
were juxtaposed by moving rows in a partially-ordered meta-matrix. Cases that are 
clustered in this way were examined as a group to determine similarities and differences. 
If the cases shared similar patterns in factors of exposure, the patterns were considered 
a common trajectory. The goal of the cross-case analysis was to identify a parsimonious 
number of trajectories with common features without forcing the groupings or producing 
finely grained distinctions. Each trajectory was examined for critical factors that influence 
exposure to the opioids and a detailed descriptive narrative of each trajectory was 
constructed. These data were presented in a two-by-two variable matrix in which each 
column and row represented different factors detailing exposure to known 
pharmacogenetically actionable opioids.  
Trustworthiness of Research 
 Trustworthiness of the research was further established through a series of 
published techniques87, including establishing credibility, transferability, dependability, 
and confirmability. Credibility (confidence in the truth of the findings) was evaluated 
during frequent meetings with the dissertation co-chairs. At each meeting we discussed 
emerging patterns to see if the investigator’s conclusions were consistent with both co-
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chairs’ conclusions. Transferability (showing findings have applicability in other contexts) 
was evaluated by thorough review from interdisciplinary partners (i.e., pharmacologist 
and health economist) and will need to be further evaluated through validation studies 
with different medications and/or populations. Dependability (findings are consistent and 
could be repeated) was achieved by the investigator documenting detailed analytic 
memos throughout the analysis process to identify his thoughts about how the data was 
structured into clusters, patterns, or themes.54 Confirmability (findings are shaped by 
data and not researcher bias) was realized through a rigorous, written self-examination 
of biases and presuppositions that was discussed with both dissertation co-chairs, and 
then bracketed during data analysis. Frequent meetings were held with both co-chairs to 
review all cases independently and discuss and compare each of our conclusions in 
order to achieve intersubjective consensus. All analytic notes were also reviewed by the 
co-chairs and appropriate guidance was provided. 
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CHAPTER 2 
 This chapter presents the results of the manuscript, “Pharmacogenomics in the 
Nursing Literature: An Integrative Review,” which has been published in the August, 
2014 issue of Nursing Outlook.  
 
Full citation: 
Knisely, M.R., Carpenter, J.S., & Von Ah, D. (2014). Pharmacogenomics in the nursing 
 literature: An integrative review. Nursing Outlook, 62(4), 285-296. 
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Abstract 
 Pharmacogenomics is a rapidly growing component of personalized medicine 
and nurses must be competent to deliver genomic-focused nursing care. The purpose of 
this manuscript was to conduct an integrative review of pharmacogenomics in the 
nursing literature. A comprehensive search of the nursing literature was conducted using 
the key words pharmacogenomics and pharmacogenetics. A total of 47 unique articles 
were included. Articles represented mainly narrative reviews, with limited discussions of 
the implications for nursing practice, education, or research. As such, they provide 
limited direction for advancing either clinical practice or scientific inquiry. This review 
serves as a call to action for more systematic and empirical publications addressing 
pharmacogenomics in nursing practice, education, and research. Nurses must be 
involved in and contribute to interdisciplinary conversations and burgeoning clinical 
practice initiatives related to pharmacogenomics.  
 
Keywords: Pharmacogenomics, pharmacogenetics, personalized health care, nursing 
implications  
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Pharmacogenomics in the Nursing Literature: An Integrative Review 
Pharmacogenomics, a key component of personalized medication prescribing, 
provides the opportunity to individualize drug therapy through choosing the right drug 
and the right dose for the right person. This approach supersedes the traditional “one 
size fits all” approach and has potential to address the 20% to 95% of genetic-
associated variability in drug disposition.1, 2 Pharmacogenomics facilitates the 
identification of the most optimal treatments to decrease costly adverse drug events and 
side effects, with potential to improve medication adherence and ultimately improve 
patient outcomes while decreasing costs of care.3-5  
 Pharmacogenomics is the study of genomic variation associated with drug 
response, allowing for an understanding of how the genomic composition(s) of an 
individual or population affects the pharmacokinetic and pharmacodynamic responses to 
drugs.6, 7 Pharmacogenomics examines the entire genome and thus allows for the 
identification of variations in multiple genes affecting drug response.8 The term 
pharmacogenomics is often used interchangeably with pharmacogenetics; however, the 
concepts have distinct differences, with pharmacogenetics having a narrower focus. 
Pharmacogenetics is described as the study of variations of single genes influencing 
specific drug receptors and individual variability in drug response.6, 9  
Pharmacogenomics is increasingly being applied to clinical settings as a 
component of personalized health care. In 2000, the National Institutes of Health 
supported the development of the Pharmacogenomics Research Network (PGRN). The 
PGRN is composed of interdisciplinary scientific groups focused on understanding how 
an individual’s genes affect drug response.10 The PGRN’s work is being translated into 
practice through the Clinical Pharmacogenetics Implementation Consortium (CPIC). 
Currently, CPIC provides 17 evidence-based guidelines for gene and drug pairs, thus 
helping clinicians understand how genetic test results should be used to optimize drug 
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therapy.11 These guidelines address both individual medications (e.g., codeine and 
warfarin) and classes of drugs (e.g., selective serotonin reuptake inhibitors).12, 13 In 
addition to these guidelines, more than 100 medications now incorporate 
pharmacogenetic information on their product labels.14 Institutions in the United States, 
Canada, and Europe are using pharmacogenetic tests to guide medication-prescribing 
practices.15  
 Three foundational documents support the relevance and importance of 
pharmacogenomics for nurses at all levels and specialties: (1) Genetics/Genomics 
Nursing Scope and Standards of Practice6; (2) Essentials of Genetic and Genomic 
Nursing: Competencies, Curricula Guidelines, and Outcome Indicators16; and (3) 
Essential Genetic and Genomic Competencies for Nurses with Graduate Degrees.17 For 
example, as the largest group of healthcare providers, nurses are increasingly expected 
to understand and translate genomic developments into effective strategies benefiting 
patient care across clinical specialties and settings. Advanced practice nurses prescribe 
medications, and all registered nurses administer medications, provide education, 
promote adherence, and serve as the first line of defense in initiating actions to prevent, 
recognize, and treat adverse drug effects. Thus, nurses have a professional 
responsibility to apply pharmacogenomics to clinical practice, education, and research.   
For nursing to make clinical and scientific contributions, a baseline understanding 
of the knowledge discovery regarding pharmacogenomics in nursing is essential. The 
purpose of this integrative review was to provide a thorough examination of the state of 
the science of pharmacogenomics as reflected within the nursing literature. Specific 
aims were to critically examine within the nursing literature: (1) the concepts of 
pharmacogenomics and pharmacogenetics; (2) pharmacogenomic and 
pharmacogenetic clinical practice applications; and (3) nursing’s responsibilities in 
pharmacogenomics and pharmacogenetics. 
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Methods 
 Computer-based searches of the nursing literature were conducted in PubMed, 
the Cumulative Index to Nursing and Allied Health (CINAHL), and Ovid Nursing. The 
keywords used were pharmacogenomics or pharmacogenetics. Article inclusion criteria 
were (1) full-length article published in a nursing journal, (2) English-language, and (3) 
including content relevant to pharmacogenomics and/or pharmacogenetics. Nursing 
journals were identified through the three databases searched by selecting the 
appropriate journal category/subset limits to only include nursing journals. Nursing 
journals were chosen for inclusion because research has shown that these journals are 
highly circulated and read by nurses, and they reflect both the nursing and biomedical 
literature.18 Exclusion criteria included: (1) editorials and abstracts; (2) duplicate 
publications; and (3) no exploration of pharmacogenomics or pharmacogenetics beyond 
the definition or no detailed discussion of the concepts.  
The search yielded a total of 136 articles. Titles were screened to remove 
duplicates (n = 56). Abstracts of the remaining 80 articles were reviewed to eliminate 
ones not meeting inclusion criteria (n=12). The remaining 68 articles were read in full, 
with another 21 eliminated due to not meeting inclusion criteria. The resulting 47 articles 
were included in this review. Figure 2-1 outlines the search results and detailed 
screening process. 
 Data were abstracted from each article by the first author and verified by the 
second author. Discrepancies were resolved through discussion. Data were organized in 
tables to address the three specific aims of this review. These data were analyzed and 
integrated through coding, categorizing, and summarizing to reach conclusions. Each 
aim corresponds with a like-numbered table (e.g., Aim 1 and Table 2-1).  
 Abstracted data for Table 2-1 included information about the author(s), year, 
national origin of author(s), article type, purpose, and the definitions used for 
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pharmacogenomics and/or pharmacogenetics. If the purpose was not stated within the 
article itself (excluding abstract), “not stated” was noted in this column. If the authors did 
not define the concepts, those columns were left blank. Table 2-1 shows data for articles 
published in the last year (2013) and the complete table is available upon request from 
the authors.  
 Table 2-2 was created to summarize discussions about clinical practice 
presented in the articles and included information about patient population, medication 
classes, and practice guidelines described in the article. Patient populations were 
grouped into five different categories (mental health, cardiovascular, oncology, 
surgical/anesthesia, and obstetrics). Because most articles referred to adults only, we 
noted especially where pediatric patients were included within Table 2-2. The clinical 
practice guideline discussions were coded as (1) not discussed, (2) partially discussed 
(briefly mentioned the need or actual practice guidelines), or (3) detailed discussion 
(provided detailed examples of practice guidelines).  
 Data abstracted into Table 2-3 included the implications of pharmacogenomics 
for nursing practice. Articles were reviewed for (1) focus on functional role in nursing – 
direct care nurses or nurses in general (with no particular focus on a nursing role), 
advanced practice nurses, and/or researchers; (2) focus of implications (practice, 
education, research); and (3) the temporal saliency of the implications. Examples of 
practice implications included topics such as patient assessment, education, and 
integrating knowledge for the purpose of prescribing medications. Education implications 
included discussions around implementing pharmacogenomic content in nursing 
curricula, continuing education, and certification and licensing exams. Research 
implications included discussions of the impact of pharmacogenomic knowledge on 
research or directions for future research. 
29 
Results 
Description of Sample  
 This literature review resulted in a homogeneous sample of articles, with 91.5% 
(n = 43) being narrative reviews.4, 19-60 No narrative review article included a description 
of systematic evaluation methods such as search strategies used, number of articles 
retrieved, and reasons for attrition or final sample selection.61 The remaining articles 
included 4% (n = 2) case studies53, 62, 2% (n = 1) a conceptual framework63, and 2% (n = 
1) an in vitro pharmacogenetic study.64 According to Melnyk & Fineout-Overholt’s Rating 
System for the Hierarchy of Evidence65, only one article64 provided Level III evidence 
through representing an in vitro pharmacogenetic study, whereas all other articles 
provided the lowest level of evidence, Level VII,  or narrative and/or opinion manuscripts. 
The majority were published after 2009 (66%, n = 31) and originated in the United States 
(87%, n = 41). However, there were four different countries represented – Brazil, New 
Zealand, United Kingdom, and the United States - and 4% (n = 2) of the articles45, 57 
represented international collaborations. These findings support the international 
relevance of this topic. 
 Overall, the purpose of most articles was to review or explore clinical aspects of 
pharmacogenomics and/or pharmacogenetics. However, 40% (n = 19) did not have a 
clearly articulated purpose. One article31 included a purpose statement within the 
abstract but not within the text of the article.  
 Only two articles described a theoretical foundation. Davies and colleagues63 
presented a conceptual framework to “incorporate pharmacologic findings and 
pharmacogenetic evidence related to atypical antipsychotic drugs (ADDs) into advanced 
psychiatric nursing practice” (p. 98). Davies, Conley, and Roth64 used a systematic 
approach to conduct in vitro pharmacogenetic experiments to determine whether allelic 
variants in the 5-hydroxytryptamine receptor altered the pharmacology of certain ADDs.   
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Aim 1 Results: Concepts of Pharmacogenetics and Pharmacogenetics 
 As shown in Table 2-1, there was wide variation in conceptual definitions. 
Pharmacogenomics was defined in 21% (n = 10) of articles, pharmacogenetics in 25.5% 
(n = 12), both concepts defined in 25.5% (n = 12), and neither concept was defined in 
25.5% (n = 12). One article, Beery and colleagues23, used the two concepts 
interchangeably and referred to them as “pharmacogenetic/pharmacogenomic...” Both 
the terms pharmacogenomics and pharmacogenetics were most widely used in 
describing the science or study of genetic variations and the effects on drug responses. 
In addition, these concepts were described in relation to the clinical applicability and its 
effect on treatment outcomes. 
 Three distinct attributes, or defining characteristics, emerged from the definitions 
of pharmacogenomics and pharmacogenetics. These included (1) science/study, (2) 
genomic/genetic, and (3) pharmacology. Science is defined as “knowledge or system of 
knowledge covering general truths of general laws”66 whereas study is defined as “such 
application in a particular field or to a specific subject.”67 Sixty-two percent (n = 29) of 
articles defined pharmacogenomics and/or pharmacogenetics using these terms.  
 A variety of terms was used to describe the genetic/genomic attributes of 
pharmacogenomics and pharmacogenetics. Genetics is defined as the study of 
individual genes and their impact on a single-gene disorder, whereas genomics is the 
study of all genes in the human genome and their interactions with each other and the 
environment.6 The concept and knowledge of genomics is much broader than genetics 
and these differences were not reflected in the definitions of pharmacogenomics and 
pharmacogenetics, thus obscuring any differentiation or clarity between the two 
concepts.  
 The definitions of pharmacogenomics included the terms chromosomal, gene, 
genes, genomic, genetic, genotype, DNA/RNA, and polymorphisms to describe 
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variations in individuals’ genetic profiles. The definitions of pharmacogenetics used very 
similar terms:  gene, genes, genetic, and DNA. Again, this variety of terms obscured 
clarity and led to inconsistencies within and between the definitions. 
 In addition to the knowledge of genetics and genomics, an understanding of the 
pharmacology of medications is essential. Pharmacology pervades all aspects of the 
study and use of drugs in humans, and this aspect is studied by considering the 
pharmacokinetic and pharmacodynamic effects of medications.68 Within the definitions of 
pharmacogenomics and pharmacogenetics, these drug relationships were described in a 
variety of ways using terms including: variations in drug toxicity, drug behavior, adverse 
drug reactions, drug effects, and drug responsiveness. 
 Overall, the definitions of the two concepts, pharmacogenomics and 
pharmacogenetics, were not sufficiently distinguished so as to clarify the concepts as 
being distinct from one another. Standing alone, the three defining characteristics – 
study/science, genetic/genomic, and pharmacology - should lead to each individual 
concept69; unfortunately, these defining attributes did not always provide the clarity 
needed to differentiate between pharmacogenomics and pharmacogenetics. 
Aim 2 Results: Pharmacogenomic and Pharmacogenetic Clinical Practice 
Applications 
 Fifty-seven percent (n = 27) of articles focused on specific patient populations 
(see Table 2-2). The remaining articles (43%) either provided a broader overview 
crossing multiple patient populations or referred to no particular patient population. The 
application of pharmacogenomics in the pediatric population was discussed only in three 
articles (6%).55, 58, 70 In articles focusing on specific populations, mental health and 
cardiovascular patients were the most frequently discussed. In addition, anticoagulants, 
psychotropic medications (e.g., antidepressants and antipsychotics), opioids, and 
antihypertensives were the medication classes most emphasized. 
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 The use of interdisciplinary clinical practice guidelines to guide medication dosing 
based on pharmacogenetic results was not discussed in most articles, with only 19% (n 
= 9) addressing either the need for or use of clinical practice guidelines. Warfarin dosing 
guidelines (warfarindosing.org) were the most frequently mentioned.23, 33, 39, 41, 53 Kelly38 
was the only article specifically addressing the Clinical Pharmacogenetics 
Implementation Consortium (CPIC) guidelines for codeine dosing. These CPIC 
guidelines were noted to be useful in facilitating translation of pharmacogenomic 
knowledge to clinical practice.11 The first CPIC guideline was established in 2010, and 
thus we recognize that articles published prior to this date would not reflect these 
guidelines. 
Aim 3 Results: Nursing’s Responsibilities in Pharmacogenomics and 
Pharmacogenetics 
 Thirty-six articles (76.5%) included a discussion of nursing implications affecting 
direct care nurses or nurses in general. Advanced practice nurse (APN) implications 
were presented in 42.5% (n = 20) of articles, yet only 4% (n = 2) specifically addressed 
the role of the nurse researcher.  
 Discussions about nursing implications were organized into three categories – 
practice, education, and research. Only one article provided detailed discussion30, and 
another briefly discussed implications for all three categories.60 No other articles 
addressed all three categories.  
Practice implications were discussed in 94% (n = 44) of the articles, with an 
overwhelming consensus that nurses need to have the ability to apply 
pharmacogenomic knowledge in practice such as in nursing assessments and detailed 
patient and family histories.4, 21, 26, 30, 32, 40, 41, 43, 48, 52-55, 58 In addition, several articles noted 
that it is essential for nurses to have a keen ability to evaluate the effectiveness of 
pharmacogenomic treatments such as patient responses to medications and 
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identification of drug reactions.31, 33, 36, 43, 47, 48, 53, 55, 58 Others noted that nurses are and 
will continue to be integral to providing patient and family education around this topic, 
including interpretation of pharmacogenetic results, providing information on 
medications, and explaining why others are taking different medications or dosages for 
the same condition.33, 54, 63 Finally, several articles noted that APNs who prescribe 
medications should have a fundamental understanding of the principles of pharmacology 
and genetics in order to incorporate patient environment and genetics when selecting 
medications and dosages.22, 32, 39, 49, 70  
 Implications for nursing continuing education were less frequently included 
(25.5%, n = 12 articles). Recommendations were that pharmacogenomic and 
pharmacogenetic information should be reflected in educational initiatives preparing 
nurses at all levels4, 44, 48 and in nursing curricula.23, 56 Suggestions for incorporating this 
content into nursing curricula included the need for faculty to have additional education 
and specific training regarding the application of genomic models to practice.41 Finally, 
the articles noted that education should include ethical and legal aspects of genomic 
medicine because nurses will be held legally and professionally responsible for 
understanding the pharmacogenomics of drugs administered.19, 27  
 Research implications were discussed in 32% (n = 15) of articles. These articles 
noted that nurses are integral to the success of personalized medicine and should 
conduct and participate in collaborative research.4, 22, 60 The need for pharmacogenomic 
studies to evaluate the effectiveness of genetic and genomic technologies, information, 
interventions, and outcomes was discussed.26, 50, 63, 64 Specifically, articles recommended 
that future studies explore the safety, efficacy, and effectiveness of pharmacogenomic 
treatments to provide evidence of clinical utility.29, 36, 50, 64 A final research 
recommendation was to study the ethical, legal, and social implications of the use of 
pharmacogenomics.29, 30  
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 In regard to the temporal saliency of these implications, the majority of the 
implications were provided in the context of the future (62%, n = 29). In these articles, 
pharmacogenomics and pharmacogenetics were seen as far off in the future rather than 
in the here and now of clinical practice, education, or research. Twenty-eight percent (n 
= 13) of articles presented nursing implications for current practice and 10% (n = 5) of 
articles included both.  
Discussion & Future Directions 
 The overall conclusion of this integrated review is that a call to action is needed 
for nurses to fully embrace the burgeoning interdisciplinary field of pharmacogenomics.  
Our current literature is limited in number, type, and scope of articles. Narrative reviews 
are criticized for their possible selection bias, wherein all available information is not 
reviewed and instead authors may preferentially cite data to support certain points or 
opinions.71 The overwhelming lack of theory and empirical studies greatly limits the 
establishment of a robust foundation to build upon. Although nurses may be publishing 
theoretical and/or data-based articles in journals that are not nursing-specific (i.e., 
interdisciplinary journals), the overwhelming majority of articles in nursing journals 
reiterated rather than systematically reviewed existing information and did not generate 
theoretical or empiric knowledge. This stands in stark contrast to the knowledge being 
generated in other fields. For example, Preskorn and Hatt72 conducted a search of 
PubMed with the keyword pharmacogenomics and found a significant increase in 
knowledge as represented by the growing number of annual publications since the late 
1990s. Approximately 400 articles were published in 2000, which increased to nearly 
1,300 publications in 2012. When we repeated their search in PubMed on January 20, 
2014, results yielded 1,370 publications in 2013, indicating the immediate and growing 
relevance of pharmacogenomics. Thus, our overwhelming conclusion is that, although 
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pharmacogenomic knowledge has exploded over the last decade, articles published in 
nursing journals do not reflect this trend. 
 As nursing embraces pharmacogenomics, it is crucial that consistent terms and 
definitions be used. Similar to other disciplines73, conceptual confusion between 
pharmacogenomics and pharmacogenetics was evident. In the nursing literature, these 
two concepts were used interchangeably and defined inconsistently, with different terms 
used to describe the same or similar key attributes. This conceptual confusion of central 
concepts contributes to difficulties in developing a foundational framework. 
Pharmacogenomic studies investigate multiple genes or the entire genome and can be 
useful in examining how genetic variations effect drug response among populations, for 
instance, how drugs may affect different racial or ethnic groups.8 Pharmacogenetic 
studies can provide a more focused approach by identifying individual gene variation 
and its influence on a certain medication, such as a CYP2D6 variation effect on the 
metabolization of codeine.  Our recommendation for future work is for nursing to use 
agreed-upon definitions of pharmacogenomics and pharmacogenetics from national 
organizations such as the American Nurses Association6, National Human Genome 
Research Institute8, or the Pharmacogenomics Knowledge Base website supported by 
the National Institutes of Health (NIH).13  
The available literature did provide a variety of examples of how to apply 
pharmacogenomics to practice, education, and research. However, articles provided 
only a superficial expression of the roles and responsibilities outlined in the International 
Society of Nurses in Genetics (ISONG) and American Nurses Association’s 
Genetics/Genomics Nursing Scope and Standards of Practice6, the Essentials of 
Genetic and Genomic Nursing: Competencies, Curricula Guidelines, and Outcome 
Indicators16, and Essential Genetic and Genomic Competencies for Nurses with 
Graduate Degrees.17 These guidelines provide the detailed nursing scope of practice in 
36 
genomics and minimum genetic and genomic competencies expected of every nurse, 
with the latter providing specific competencies for advanced practice nurses, clinical 
nurse leaders, educators, administrators, and scientists. For example, nurses should be 
able to help patients understand how results of pharmacogenetic tests may impact 
medication changes and/or dose changes in addition to ensuring patients possess and 
are using the correct medications and doses. Advanced practice nurses must be able to 
advocate for pharmacogenetic testing and base medication prescriptions on those 
results. Further work is needed to more clearly elucidate nursing’s roles and 
responsibilities in the body of literature addressing pharmacogenomics in nursing. 
Advancing and implementing components of personalized health care, such as 
pharmacogenomics, largely depends upon contributions from interdisciplinary 
stakeholders.74, 75 Pharmacogenomics is directly relevant to the work nurses do every 
day and the research priorities of the National Institute of Nursing Research.76 The key 
role nurses play in promoting self-management during acute and chronic illness was 
emphasized in a recently released request for applications, RFA-NR-14-002, Centers of 
Excellence in Self-Management Research (http://grants.nih.gov/grants/guide/rfa-
files/RFA-NR-14-002.html). Because medication management is a key component of 
self-management, pharmacogenomics is pertinent to nurses’ contributions in promoting 
self-management. Clinical care, education, and research interventions must address the 
issue of pharmacogenomics for nurses and nursing research to continue to promote 
excellence in nursing care.  
Policy makers, educators, and nursing administrators in health care systems 
need to ensure that nurses are appropriately prepared to participate in interdisciplinary 
conversations and initiatives related to pharmacogenomics in health care. It is important 
that licensing examinations and advanced specialty certifications reflect current trends in 
health care, therefore having pharmacogenomic-related content is important. This 
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content should be based on the competencies documents listed above.6, 16, 17 Educators 
should integrate pharmacogenomic information into the curriculum, such as 
pharmacology courses, simulations, and clinical experiences. Administrators must 
ensure policies are up to date and support or provide additional continuing education 
resources so nurses develop and remain competent in pharmacogenomics.  
Limitations 
 The conclusions from this review should be interpreted in the light of some 
limitations. Articles published only in nursing journals were included. We recognize 
nurses may be publishing in non-nursing journals and nursing books. This review does 
not reflect that work or work published by other disciplines. Moreover, this review does 
not represent ongoing or existing unpublished work, published editorials or abstracts, or 
dissertations. The review was limited to only articles published in English and thus is not 
representative of other non-English articles.  
Conclusion 
This integrative review was the first to evaluate the state of the science of 
pharmacogenomics in the nursing literature. The findings identified the limitations of the 
nursing literature and suggest a call to action is needed for nursing to recognize and 
embrace this important and burgeoning field. Pharmacogenomics can no longer be 
looked at as a practice on the horizon since it is already being implemented in a variety 
of capacities. To meet responsibilities for practice, education, and research, nurses must 
engage in interdisciplinary conversations involving pharmacogenomics. Research aimed 
at the nursing implications of pharmacogenomics is needed to support the developing 
responsibilities of nurses in practice.   
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Figure 2-1. 
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Table 2-1. 
Evaluating the Concepts of Pharmacogenomics and Pharmacogenetics in Nursing Articles Published in 2013 
Author, Date 
Country 
Type of 
Article 
Purpose Definition of 
Pharmacogenomics  
Definition of 
Pharmacogenetics 
Chadwell, 2013 
U.S.A 
Narrative 
Review 
Provide an overview of 
personalized medicine, its 
relevance to advanced nursing 
practice, and resources related 
to personalized medicine, 
including genetics and 
genomics. 
 
the general study of all the 
many different genes that 
determine drug behavior 
the study of inherited 
differences in drug 
metabolism and response 
Cheek, 2013  
U.S.A. 
Narrative 
Review 
Focus on how 
pharmacogenomics can help 
nurses provide better care for 
patients. 
tailoring medications to a 
patient’s genomic 
information, is a significant 
and growing area of 
research with the potential 
to improve patient 
outcomes 
 
the field of study dealing 
with the variability of 
responses to medications 
due to variation in single 
genes 
Kaplan et al., 
2013,  
U.S.A. 
Narrative 
Review 
Review the pharmacology of 
tamoxifen, the genetics and 
physiology of CYP2D6, and the 
clinical implications of both for 
women with hormone receptor-
positive breast cancer. 
 
  
    Table continues 
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Kelly, 2013  
U.S.A. 
Narrative 
Review 
Not stated. the study of how an 
individual's genetic 
inheritance affects the 
body's response to drugs 
 
 
Mutsatsa et al., 
2013 
U.K. 
Narrative 
Review 
Review the progress made in 
research towards understanding 
how genetic factors influence 
psychotropic drug response.  
 
 science dedicated to the 
identification of genes 
influencing response to 
medication 
Santos et al., 
2013 
Brazil, U.S.A. 
Narrative 
Review 
Introduce nurses to how -
genomics is currently integrated 
into cancer care from 
prevention to treatment and the 
influence on oncology nursing 
practice. 
 
study of how genomic 
factors (including SNPs) 
and acquired mutations in 
tumors determine an 
individual’s response or 
toxicity to drugs 
 
Turner, 2013  
U.S.A. 
Narrative 
Review 
Review the risks in child and 
adolescent psychiatric 
prescribing and review how 
analysis of medication 
interactions with the CYP450 
enzyme system can improve 
safety and efficacy. 
an area of science focused 
on studying variations in 
genes that impact 
individual drug response, 
identifying new drug 
transporters, and studying 
metabolizing enzymes 
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Table 2-2. 
Summary of Pharmacogenomic Clinical Practice Discussions in the Nursing Literature 
Author, Date Patient Population1 Medication Classes CPIC/Practice 
Guidelines2 
Ama et al., 2010 surgical patients (pseudocholinesterase 
deficiency, malignant hyperthermia, 
analgesics, PONV*), 
anesthetics, opioids, 
antidepressants 
□ 
Anderson, 2011 obstetrics   opioids  □ 
Anderson-Pompa, 
2008 
surgical patients – malignant hyperthermia anesthetics □ 
Beery, et al., 2004   □ 
Beery, et al., 2011  opioids, anticoagulants, 
antidepressants 
◘ 
Bray et al., 2008 mental health psychotropic medications □ 
Chadwell, 2013  anticoagulants □ 
Cheek, 2013 cardiovascular, mental health, HIV*, oncology antiplatelet, anticoagulant, 
antidepressants, antiretroviral  
□ 
Chummun, 2011  opioids  □ 
Davies et al., 2010 mental health antipsychotics  ◘ 
Davies et al., 2011 mental health antipsychotics  □ 
Ensor et al., 2009  cardiovascular antiplatelet  □ 
Fleeman et al., 2009   anticoagulants, antipsychotics, 
antidepressants, and tamoxifen  
◘ 
Frazier et al., 2004  antihypertensives □ 
Frazier et al., 2009 cardiovascular  antihypertensives □ 
Howe, 2011 cardiovascular  antihypertensives, digoxin, 
anticoagulants, antiplatelet, lipid-
lowering agents, & antiarrhythmic 
□ 
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Howington et al., 
2011 
 cancer agents for leukemia & breast 
CA, antivirals, Anticoagulants, 
antihypertensives  
◘ 
Howland, 2006 mental health antidepressants & antipsychotics □ 
Kaplan et al., 2013 oncology – breast cancer tamoxifen ◘ 
Kayser, 2007 cardiovascular  anticoagulants, antiplatelets, 
antihypertensives, & antiarrhythmic  
□ 
Kelly, 2013  opioid ◘ 
Krauter et al., 2011 mental health - depression antidepressants  ◘ 
Kudzma, 2001 Cardiovascular disease – hypertension antihypertensives □ 
Kudzma et al., 2009  anticoagulant, Opioids, Statin drugs, 
tacrine, cancer treatments 
(azathioprine, irinotecan, 5-
Fluorouracil) 
■ 
Kurnat-Thoma, 2011  anticoagulant  □ 
Landino et al., 2011 mental health psychotropic medications □ 
Lea, 2000   □ 
Lea, 2005  opioids □ 
Lea, 2009  chemotherapy, cetuzimab, and 
herceptin 
□ 
Lea et al., 2011  anticoagulant, anticonvulsants, 
antidepressants, antihypertensives, 
analgesics, cancer therapy 
□ 
Miaskowski, 2009 cancer pain opioids □ 
Mutsatsa et al., 2013 mental health antipsychotics, antidepressants, & 
mood stabilizers 
□ 
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Nicol, 2003  antipsychotics, antidepressants, 
anticoagulants, opioid, proton pump 
inhibitor, antiseizure medications 
□ 
Novak, 2007   □ 
O’Malley, 2011  antiplatelet □ 
Petska, 2010   □ 
Prows et al., 2004   □ 
Prows, 2008  psychotropic medications & 
anticoagulants 
□ 
Prows et al., 2008 cardiovascular anticoagulant & antihypertensives ■ 
Prows et al., 2009 mental health – pediatric psychotropic medications □ 
Prows, 2011 oncology tamoxifen, Antidepressants, 
chemotherapy  
□ 
Read, 2002   □ 
Santos et al., 2013 oncology chemotherapy agents and adjuvants  □ 
Theoktisto, 2009 ADHD* - pediatric psychotropic & psychostimulant 
medications 
□ 
Turner, 2013 mental health - pediatric psychotropic medications □ 
Wung, 2002 cardiovascular antihypertensives & Statins □ 
 
1Patient population: All patient populations are adults unless noted as including pediatric patients.  
2Extent of Discussion: No discussion (□) – no mention of clinical practice guidelines for nurses; Partial discussion (◘) – briefly 
mention clinical practice guidelines; Detailed discussion (■) – provides detailed discussion or examples of clinical practice 
guidelines 
*PONV – Post-operative nausea and vomiting; ADHD – Attention Deficit Hyperactive Disorder 
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Table 2-3. 
Pharmacogenomic Nursing Implications as Discussed in Nursing Literature 
Author, Date Nursing Role Focus of Implications  Future  Now 
Nurses Advanced Practice 
Nurses 
Researcher Practice Education Research   
Ama et al., 2010  X  X X  X  
Anderson, 2011  X  X  X X  
Anderson-Pompa, 
2008 
X   X  X X  
Beery et al., 2004  X  X  X X  
Beery et al., 2011 X   X X  X X 
Bray et al., 2008  X   X  X X X 
Chadwell, 2013  X  X X  X  
Cheek, 2013 X   X   X  
Chummun, 2011 X X  X   X  
Davies et al., 2010 X X  X  X  X 
Davies et al., 2011   X   X  X 
Ensor et al., 2009 X   X   X  
Fleeman et al., 2009 X     X X  
Frazier et al., 2004 X X X X X X X  
Frazier et al., 2009 X   X  X X  
Howe, 2011 X X  X    X 
Howington et al., 2011 X   X    X 
Howland, 2006a X   X   X  
Howland, 2006b X X  X   X  
Kaplan et al., 2013 X   X  X  X 
Kayser, 2007 X   X   X  
Kelly, 2013 X   X    X 
      Table continues 
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Krauter et al., 2011 X X  X    X 
Kudzma, 2001 X   X    X 
Kudzma et al., 2009 X   X X   X 
Kurnat-Thoma, 2011 X   X X X X  
Landino et al., 2011  X  X    X 
Lea, 2000 X   X   X  
Lea, 2005 X   X    X 
Lea, 2009 X X  X X  X  
Lea et al., 2011 X X   X  X  
Miaskowski, 2009 X   X   X  
Mutsatsa et al., 2013 X X  X   X  
Nicol, 2003 X   X X  X  
Novak, 2007  X  X   X  
O’Malley, 2011  X  X  X X  
Petska, 2010 X   X   X  
Prows et al., 2004 X   X   X  
Prows, 2008 X   X   X  
Prows et al., 2008 X   X X  X X 
Prows et al., 2009 X   X    X 
Prows, 2011 X   X    X 
Read, 2002 X   X X  X  
Santos et al., 2013 X   X   X  
Theoktisto, 2009  X  X  X X X 
Turner, 2013  X  X  X X X 
Wung, 2002 X   X X X X  
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CHAPTER 3 
 This chapter presents the results of the manuscript, “Moving Toward Widespread 
Implementation of Pharmacogenetic Testing: Understanding Patterns of Exposure to 
Pharmacogenetically Actionable Opioids.” 
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Abstract 
 Understanding and capturing the dynamic nature of medication exposure is a key 
component in evaluating the impact of pharmacogenetic testing on improving patient 
outcomes. The goal of this study was to generate a complex description of the unfolding 
of medication exposure over time in persons newly prescribed the pharmacogenetically 
actionable opioids of codeine or tramadol using a qualitative person-oriented approach. 
We used qualitative within- and cross-case analyses of six months of retrospective data 
from de-identified electronic health records and pharmacogenetic genotype data from 
banked DNA samples of 30 adult patients. We identified an overarching typology with 
eight  groups of patients that had one of five opioid prescription patterns (singular, 
episodic, switching, sustained, or multiplex) and one of three types of medical emphasis 
of care (pain, comorbidities, or both). The findings highlighted the heterogeneity and 
variations among the sample prescribed these medications and advanced the argument 
that medication exposure is not static, but rather dynamic and multidimensional. The 
knowledge gained can be used to guide the development of medication exposure 
measures and inform studies seeking to identify and develop personalized interventions 
in this population. 
 
Keywords: Medication exposure, pharmacogenomics, opioid, clinical implementation, 
pain management 
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Moving Toward Widespread Implementation of Pharmacogenetic Testing: 
Understanding Patterns of Exposure to Pharmacogenetically Actionable Opioids 
Evidence-based guidelines have been developed for the use of pharmacogenetic 
testing to guide the prescription of certain opioid therapies in clinical practice. 
Pharmacogenetic testing identifies individual genetic variations that are associated with 
drug metabolism and response.1 Pharmacogenetic testing is a particularly promising 
approach to help address wide interindividual differences in responses to some opioid 
medications and could thus lead to improved analgesia and mitigate costly adverse drug 
effects.2 Pharmacogenetically actionable opioids are those that have strong evidence 
based guidelines to guide drug or dosing changes based on pharmacogenetic test 
results.3, 4 Codeine and tramadol are two commonly used pharmacogenetically 
actionable opioids.  
 Medication exposure can be broadly characterized as the condition of being 
subjected to a medication. Medication exposure includes multiple factors such as the 
medication and dose prescribed, the medication regimen, and changes in the regimen 
over time.5 Despite the fact that medication exposure is a multidimensional process that 
changes over time, measures of medication exposure typically capture single event 
medication prescriptions as a dichotomous variable (yes/no prescribed) or medication 
counts (total number of medications prescribed).6, 7 
 To date, studies of the potential efficacy and effectiveness of pharmacogenetic 
testing have been limited by the failure to examine the complexities of medication 
exposure and the lack of an adequate measure of medication exposure.8-11 For example, 
Schildcrout et al.11 used medication counts of 56 different medications, including 
tramadol and codeine, to predict the number of potential adverse drug events that could 
be avoided through preemptive pharmacogenetic testing. Additionally, in a study that 
sought to model the benefits of pharmacogenetic testing on antidepressants, exposure 
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to selective serotonin reuptake inhibitors (SSRIs) was captured dichotomously through 
an on/off treatment measure.10  
Pharmacogenetic studies have also failed to consider factors that are likely to 
influence the effects of pharmacogenetic testing on patient outcomes including the 
complexity of patient’s clinical profile and the healthcare context in which the medication 
is prescribed.6, 12, 13 For example, the cost of pharmacogenetic testing may be a 
challenge in low resource facilities or those that treat patients with complicated medical 
histories and multiple comorbidities, such as is often the case in federally qualified or 
safety-net health systems.14 Further, the outcomes of pharmacogenetic testing for opioid 
exposure are likely to be influenced by the non-pain-related conditions for which patients 
are being treated using non-opioid pharmacologic agents. For example, the potential for 
drug-drug interactions are likely to increase in patients treated for a number of 
comorbidities and this risk could impact medication exposure patterns.15  
Therefore, a different, more complex conceptualization of opioid exposure is 
needed to guide subsequent development of improved measures of opioid exposure.6, 16 
One research approach that captures the complexities of health-related dynamic 
phenomena is the person-oriented approach. This approach is based on two 
assumptions. First, that persons should be considered holistically; that is, all aspects of 
their being – their genetic makeup, histories, and behaviors, as well as the contextual 
risk and protective factors they encounter – interact synergistically to constitute human 
experience.17 Second, that human functioning is fluid over time due to developmental 
processes and constant changes in the person-environment system.18 The person-
oriented approach seeks to uncover common patterns of interacting characteristics and 
behaviors in heterogeneous samples by identifying subgroups within the sample that 
share common patterns.17, 19 The subgroups are often then presented in a typology to 
allow for an in-depth description of the characteristic patterns of each group. The 
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person-oriented approach can use either pattern-based quantitative methods (e.g., latent 
class analysis, cluster analysis, or configural frequency analysis) or qualitative methods 
(e.g., within-case and cross-case analysis) to identify meaningful subgroups within 
heterogeneous samples.17, 20, 21  
In health-related research, the person-oriented approach provides an alternative 
to the more traditional variable-oriented approach in which variables represent 
characteristics or behaviors that vary within groups or across time and are the primary 
analytic unit of study. In variable-oriented approaches, linear relationships among 
variables are studied and model testing yields causal inferences.22 Person-oriented 
methodologists argue that variable-oriented approaches are limited by the assumption 
that samples are homogenous in regards to the relationships among variables and by 
the fact that group statistics and aggregate data do not allow inferences about any one 
case.23, 24 A person-oriented approach, which clusters persons with similar 
characteristics, can provide conclusions about subgroups that are interpretable at the 
level of the individual.17, 19 While a variable-oriented approach could identify factors that 
predict the efficacy of pharmacogenetic testing, a person-oriented approach will yield a 
typology of subgroups that cluster on relevant characteristics of medication exposure, 
capture the complex nature of exposure to pharmacogenetically actionable opioids, and 
account for the context in which the exposure to these medications occur. 
 Our goal was to generate a complex description of the unfolding of medication 
exposure over time in persons newly prescribed codeine or tramadol. The primary 
purpose of this study was to employ a qualitative person-oriented approach to develop a 
typology that identified meaningful subgroups that share common patterns of medication 
exposure within a sample of patients newly prescribed a pharmacogenetically actionable 
opioid.   
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Methods 
 This retrospective, 6-month, longitudinal analysis of de-identified, electronic 
health records and banked DNA samples used a qualitative, person-oriented approach 
and did not require Institutional Review Board review. The theoretical and 
methodological components of the person-oriented approach are described in detail 
elsewhere.25  
Setting 
 This study was conducted in a large, Midwestern safety-net healthcare system 
where widespread implementation of pharmacogenetic testing was occurring. This 
setting was chosen because this health system predominately serves low-income, or 
uninsured or underinsured individuals who are at greater risk for poor health, emergency 
room visits, frequent hospital admissions, and adverse outcomes from disease and their 
treatments.26-28 This healthcare system also has the advantage of having robust data 
repositories allowing for linkage of patients’ health records to banked DNA samples. 
Sample  
 A multiple-case sample was produced through randomly selecting a subset of 
de-identified electronic health records and banked DNA samples from patients (cases). 
Inclusion criteria for cases were: 1) part of a managed care program for individuals 
falling at or below 200 percent of the federal poverty level; 2) first prescription of record 
for codeine or tramadol in at least one of primary care clinics part of a large safety-net 
health system; 3) had a banked blood sample; 4) age 21 and older; and 5) had no 
previous documentation of substance abuse in the electronic medical record. A ‘first 
prescription of record’ was defined as either codeine or tramadol being prescribed 
between January 1, 2010 and December 31, 2014 and no information in the patient’s 
record that indicated that either medication had been previously prescribed. Cases with 
known substance abuse were excluded because that population may have distinct 
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patterns of exposure and it would have been difficult to determine whether their 
exposure to opioids was related to appropriate use for analgesia or for other non-
medical reasons.29 There were a total of 118 cases that met the inclusion criteria. 
Published recommendations for a multiple-case sample range from 10-30 cases due to 
the required in-depth analysis as the complexities from larger samples would become 
unwieldy.21 Thus, this study included data from 30 cases.  
Data & Research Processes 
 Data that reflected factors pertinent to exposure to pharmacogenetically 
actionable opioids were obtained for each of the 30 cases from existing data repositories 
and through completion of CYP2D6 pharmacogenetic genotyping of DNA samples. 
Factors with potential to influence exposure to opioids were identified through an 
extensive review of the literature, including patient characteristics (e.g., demographics, 
past medical history, and pharmacogenetic genotype)30-34, medication characteristics 
(opioid information, co-prescribed medications, changes in drug regimen, drug-drug 
interactions)16, 35, 36, clinical responses (e.g., pain intensity and adverse drug effects)37, 
and healthcare utilization.38  
 The main data repository accessed for data was the Indiana Network for Patient 
Care, which is an information exchange that captures and integrates varying levels of 
data from the safety-net health system and from more than 25,000 physicians, 106 
hospitals, 110 clinics and surgery centers as well as other healthcare providers across 
Indiana.39 Additionally, other clinical and administrative data repositories from the safety-
net health system directly associated with the managed care program were accessed. A 
trained clinical data analyst accessed all data and used an existing process to de-identify 
it prior to releasing it to the research team. All electronic health records and DNA 
samples were provided a unique study identification number, allowing for the linkage of 
the two. Additionally, all dates reflecting interactions with the system of care were shifted 
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by a random number unknown to the investigators. This allowed for the timing of events 
(e.g., healthcare utilization dates, prescription dispense dates) to remain accurate in 
sequence while de-identifying the exact dates. 
 Electronic health records. Six months of electronic health record data for each 
case were extracted – starting with the date of the new prescription for either codeine or 
tramadol and ending six months later. To reflect the person-level factors pertinent to 
medication exposure, we obtained all data fields (factors) over the six months that 
captured patient characteristics, medication characteristics, clinical responses, and 
healthcare utilization. Each of these is described below.  
 Patient characteristics included age, gender, race, ethnicity, and past medical 
history. The age of the individual at the time of the first prescription for tramadol and 
codeine was used. Additionally, the past medical history recorded at every healthcare 
encounter was captured through documented International Classification of Diseases – 
9th Revision (ICD-9) codes. 
 Medication characteristics were captured through medication data from 
repositories that contain records from both health systems and outpatient pharmacies. 
The data included all available medication names, dose, dose frequency, route, supply 
amount, administration instructions, prescriber, and dates that the prescription was 
written and then dispensed. Additionally, any medication history (medication 
reconciliation) documented during a healthcare encounter was also provided. 
 Clinical responses potentially influenced by opioids included any documented 
adverse drug events and pain intensity ratings. Documented ICD-9 codes that were 
indicative of potential adverse drug events in individuals taking an opioid40, 41 during each 
healthcare encounter were used to determine if an adverse drug event occurred. Also, 
all documented pain intensities by the providers were included in the analysis. 
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 Data reflecting healthcare utilization were also captured. Because the data 
included in this study was de-identified, specific clinic names and locations were not 
provided. Each location point of care was given a unique location identification number, 
as well as categorized as primary care clinic, specialty clinic, emergency department, or 
inpatient hospitalization. The date and ICD-9 codes for admit diagnosis/chief 
complaint(s) for each visit were specified. 
 Pharmacogenetic genotype. CYP2D6 genotype was determined for all 30 
cases in this study. The CYP2D6 gene is highly polymorphic, therefore, we genotyped 
common variants that influence both codeine and tramadol drug disposition and 
response.3 Samples of extracted DNA in the amount of 350 ng/sample and a 
concentration of 10 ng/µl were released from a biobank to the research team for storage 
and analysis. The extracted DNA was further diluted to a final concentration of 5.8 ng/µl. 
Using QuantStudio (Thermo Fisher Scientific, Inc., Grand Island, NY) and following the 
manufacturer’s instructions of the Taqman Genotyping Assays (Applied Biosystems, 
Inc., Foster City, CA), genotyping was performed for the CYP2D6 alleles *2, *3, *4, *5, 
*6, *9, *10, *17, *29, and *41. These star alleles were examined because of their 
frequencies in Caucasian and African populations and their descendants.42 Quality 
controls were run for each sample batch and repeated assays were conducted on 20% 
of samples for further validation. For the genotyping, there was a 99.4% call rate. Based 
on the genotype results, a CYP2D6 activity score was calculated.3 Additionally, patients’ 
medication regimens were examined for cytochrome P450 drug-drug interactions that 
would alter the CYP2D6 enzyme activity.43 For drug-drug interactions with strong 
inhibitors of the pharmacogenetically actionable opioid, a final activity score of 0 was 
assigned. For drug-drug interactions with moderate inhibitors of the pharmacogenetically 
actionable opioid, the CYP2D6 genotype activity score was multiplied by 0.5 to 
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determine the final activity score. These final activity scores were then used to determine 
the drug metabolizing phenotype for each patient.44  
 Data analysis. Sample characteristics were described with descriptive statistics 
using SPSSTM 23.0 (IBM, Armonk, NY). The remaining data analysis was conducted by 
three of the research team members using the following iterative steps: 1) data 
condensation, 2) data display (creating matrices), and 3) drawing and verifying 
conclusions.21  
 Using all available data, within-case and cross-case analyses as described by 
Miles and colleagues21 were performed. The goal of a within-case analysis is to 
“describe, understand, and explain what has happened in a single, bounded case (p. 
100).”21 To complete this, the investigator condensed the data by selecting, simplifying, 
abstracting, and transforming it into an interpretable format. The investigator organized 
all data in a case-by-time (time-ordered) meta-matrix in which patient characteristics 
(age, gender, race/ethnicity, CYP2D6 activity score) were displayed on the vertical axis 
and all other factors (medication characteristics, clinical response, healthcare utilization) 
were organized by month on the horizontal axis. The case-by-time matrix allowed for 
visualization of all factors over the 6-month time period and the development of an in-
depth narrative description of each patient based on the salient factors that determined 
how the patients’ opioid exposure unfolded over time.  
 Using the narratives developed in the within-case analysis, cross-case analytic 
procedures were then applied. Cross-case analysis is used to cluster multiple cases into 
groups that share certain patterns or configurations.21 The goal of the cross-case 
analysis is to identify a parsimonious number of groups with common features without 
forcing the groupings or producing finely grained distinctions. A partially-ordered meta-
matrix was developed to stack the within-case (case-level) narratives to more easily 
compare across the different cases. Considering the definition of medication exposure, 
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the three research team members examined all prescription data from the 
pharmacogenetically actionable opioids (i.e., dose, timing of fills/refills, and supply 
amounts) displayed in the narrative columns of the matrix to identify repeating patterns 
of opioid exposure and, using an iterative process and group discussion, juxtaposed the 
rows that shared patterns. Cases that clustered in this way were examined as a group to 
determine similarities and differences. If the cases shared similar configurations in 
factors of exposure, the configurations were considered a common pattern. Five 
common patterns of exposure to pharmacogenetically actionable opioids were identified 
through detailed written descriptions and discussions among research team members to 
achieve intersubjective consensus.21 The patterns, which are described below, were 
labeled by the research team as singular, episodic, switching, sustained, and multiplex.   
 The research team also determined that the patients differed significantly in the 
focus of their medical care in regards to their pain, and that these differences were 
important in understanding the complexities of the exposure patterns. With a return to 
the data, the team observed patterns related to medical histories, type and indication for 
all medications prescribed, clinical responses, and type and reasons for healthcare 
encounters. It was determined that there were three main types of medical focus of care: 
a medical emphasis on pain, a medical emphasis on other comorbidities, and a medical 
emphasis on both pain and comorbidities. The cases that evidenced the five patterns of 
exposure were thus subdivided according to the type of medical emphasis of care. The 
groups were displayed on a two-by-two variable matrix (Table 3-1) in which the columns 
represented the opioid prescription patterns and the rows represented the types of 
medical emphasis of care. Each case was placed in the appropriate cell by one member 
of the research team and confirmed by the other two team members. The final product of 
the analysis, therefore, was a typology of eight groups of patients that share common 
exposure patterns and types of medical emphasis of care.   
   
61 
Results 
Sample 
The sample included 30 adults (14 males, 16 females) aged 23 to 65 years who 
had been prescribed tramadol (n = 24) or codeine (n = 6). Eighteen of the patients were 
White, 11 were Black, and one was Biracial. Twenty-six were Not Hispanic/Latino, one 
was Hispanic/Latino (n = 1), and three were of unknown ethnicity. The CYP2D6 
metabolizing phenotypes for 20 patients were normal metabolizers (activity score: 1-2), 
six were poor metabolizers (activity score: 0), two were intermediate metabolizers 
(activity score: 0.5), and two patients were ultra-rapid metabolizers (activity score: > 2). 
Mean time between when the pharmacogenetically actionable opioid prescription was 
written and dispensed was 1.6 days.  
The Typology 
The typology consists of eight groups of patients that had one of five opioid 
prescription patterns and one of three types of medical emphasis of care. The 
pharmacogenetically actionable opioid prescription patterns were labeled Singular, 
Episodic, Switching, Sustained, and Multiplex. The three types of medical emphasis of 
care were labeled Pain, Comorbidities, and Both. The defining characteristics of each of 
the patterns of opioid prescriptions and types of medical emphasis of care are displayed 
in Table 3-1. Each group is represented by a cell that includes patterns of opioid 
prescription according to the type of medical emphasis of care. In the following sections 
we provide further descriptions of each group. Individual patients are referred to by their 
study case number. Table 3-2 and Table 3-3 provides sample characteristics and Table 
3-4 provides case exemplars to illustrate the essential characteristics of each of the eight 
groups that comprise the typology. 
 Singular/Pain. Two patients were placed in this group because they received 
one, time-limited prescription for the pharmacogenetically actionable opioid while their 
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medical emphasis of care was largely attributed to pain-related conditions. Both patients 
within this group were White males and one was a CYP2D6 normal metabolizer and the 
other was an intermediate metabolizer of the pharmacogenetically actionable opioids.  
 Both patients received a prescription for tramadol for a limited period of time (≤30 
day supply). In one case, Patient 21, a 54-year-old man and a CYP2D6 intermediate 
metabolizer, was prescribed tramadol 50 mg tablet every 4 to 6 hours as needed for 
pain, whereas the other patient, Patient 26, a 61-year-old man and CYP2D6 normal 
metabolizer, was prescribed tramadol 50 mg tablet to be taken each night for severe 
pain. Neither of the patients received another prescription for a pharmacogenetically 
actionable opioid over the 6 month time frame, although each was prescribed an 
additional time-limited medication often used concomitantly to treat painful conditions 
such as naproxen (NSAID), cyclobenzaprine (muscle relaxant), and gabapentin 
(anticonvulsant).  
 The singular opioid exposure pattern for this group occurred in the context of an 
emphasis of care on their pain-related conditions. The focus of their medical visits was 
on pain-related conditions such as cervicalgia, paresthesia, and carpal tunnel syndrome, 
and their medical histories were otherwise limited. They had one to three health care 
visits over the six-month period. 
 Singular/Comorbidities. Four patients were placed in this group because they 
received one, time-limited prescription for a pharmacogenetically actionable opioid while 
the emphasis of their care was largely attributed to non-pain related comorbidities. The 
patients in this group included two White and two Black men. Three patients were 
CYP2D6 normal metabolizers of pharmacogenetically actionable opioids, and one 
patient was considered a poor metabolizer due to a drug-drug interaction.  
 Each patient in this group received a prescription for either tramadol (n = 3) or 
codeine (n = 1) for a circumscribed period of time (10-30 days). None received an 
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additional prescription of a pharmacogenetically actionable opioid. Other than one 
patient who was prescribed cyclobenzaprine for muscle spasms 3 months following a 
tramadol prescription, no other medications for pain or discomfort were prescribed to any 
patient within this group.  
 The singular opioid exposure pattern for the four patients in this group occurred 
in the context of a medical emphasis on non-pain-related comorbidities. While their pain 
was treated as described above, the focus of much of their treatment was on other 
diseases or illnesses. Some of the patients were treated for several conditions affecting 
multiple body systems. For example, Patient 14, a 62-year-old White man, sought care 
for dermatophytosis on the foot, hypertension, diabetes, and diabetic retinopathy. Others 
were treated for one overarching comorbidity such as HIV. The patients in this group had 
between 5 and 10 different visits during the six-month period and were prescribed 
between 6 and 10 different medications. One patient had a cytochrome P450 drug-drug 
interaction between codeine and bupropion, which was prescribed as a smoking 
cessation aid. Bupropion is a strong inhibitor of codeine and could reduce its analgesic 
effects. 
 Singular/Both. Three patients were placed in this group because they received 
one, time-limited prescription for a pharmacogenetically actionable opioid while the 
medical emphasis of their care was on both pain and other comorbidities. Two of the 
patients in this group were White women, and one was a White man. All the patients 
were CYP2D6 normal metabolizers of the pharmacogenetically actionable opioids. 
 Each patient in this group received a prescription for tramadol (n = 2) or codeine 
(n = 1) for a relatively short period of time (6-15 days). None of the patients received 
another prescription for a pharmacogenetically actionable opioid or any other opioid, and 
few had other medications prescribed for pain. Patient 06, a 40-year-old White female, 
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and Patient 24, a 40-year-old White male, were also prescribed gabapentin for 
fibromyalgia and neuralgia, respectively. 
 The singular opioid pattern occurred for these three patients in the context of a 
medical emphasis on both pain and other comorbidities. These patients had 4 to 10 
visits for various reasons. For example, Patient 30, a 61-year-old White woman, visited a 
primary care clinic three times for abdominal pain related to an infection and esophageal 
reflux; an outpatient specialty clinic five times for abdominal pain, chest pain, 
neuralgia/neuritis, and shortness of breath; and the emergency department once for 
abdominal pain and rectal bleeding. The patients were prescribed 9 to 12 different 
medications for different comorbidities. For example, Patient 06, a 40-year-old White 
woman, was prescribed 12 different medications for pain, depression, thyroid disease, 
vitamin supplementation, infection, and allergies.  
 Episodic/Pain. Three patients were placed in this group because they received 
multiple intermittent or discontinuous prescriptions for pharmacogenetically actionable 
opioids while their emphasis of care was largely attributed to pain-related conditions. 
The patients in this group included two Black women and one White man. Two patients 
were CYP2D6 normal metabolizers and one was considered an ultra-rapid metabolizer 
of the pharmacogenetically actionable opioids.  
 Each patient in this group received at least two separate prescriptions for 
tramadol several months apart. For example, Patient 5, a 46-year-old Black woman who 
was a CYP2D6 ultra-rapid metabolizer, was prescribed and filled a 30-day supply of 
tramadol 50 mg 1 tablet every 8 hours as needed for pain in August, and did not receive 
or fill another prescription for tramadol until 5 months later (January). Two of the patients 
were also prescribed an opioid other than tramadol over the 6-month time frame. For 
example, Patient 10, a 51-year-old Black female, was prescribed oxycodone and 
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codeine. All three of the patients also received an anti-inflammatory medication used to 
treat pain such as naproxen, ibuprofen, or piroxicam. 
 The episodic opioid exposure pattern for the three patients in this group occurred 
in the context of a medical emphasis on pain-related conditions. The focus of the 
healthcare visits was primarily on their joint pain (e.g., shoulder and leg/knee). At these 
visits, they rated their pain from 7/10 to 10/10. For example, Patient 10, a 51-year-old 
Black female, sought care three times at the primary care clinic and 1 time at a specialty 
care clinic for joint pain in the left leg. At two of the primary care visits, she reported a 
pain intensity rating of 10/10. The patients in this group had two to five visits healthcare 
visits over the six-month period. 
 Episodic/Both. Ten patients were placed in this group because they received 
and/or refilled multiple intermittent, or discontinuous, prescriptions for 
pharmacogenetically actionable opioids while having a medical emphasis of care on 
both pain and other comorbidities. The patients in this group included nine women and 
one man. Six of the patients were White and four were Black. Eight of the patients were 
CYP2D6 normal metabolizers, two were poor metabolizers due to CYP2D6 genotype 
variation, and two additional patients were considered poor metabolizers due to a drug-
drug interaction with a strong inhibitor of the opioid. 
 Each patient in this group received at least two separate prescriptions for 
tramadol (n = 8) or codeine (n = 2) that were prescribed or refilled several months apart. 
For example, Patient 18, a 56-year-old White woman, was given a 30-day prescription 
for Tramadol 50 mg 1 tablet twice a day as needed for pain that she refilled over three 
months later. Patient 01, a 61-year-old White woman, received and filled two separate 
prescriptions for tramadol over four months apart. Five days following the second 
prescription, she had a primary care visit related to an adverse effect of the opioid, but 
the details of the adverse effect are unknown. In addition to the pharmacogenetically 
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actionable opioids, most of the patients in this group were prescribed other pain 
medications including anti-inflammatory medications such as ibuprofen, piroxicam, or 
naproxen.   
 The episodic opioid exposure pattern for this group occurred in the context of a 
medical emphasis on both pain and other comorbidities. The pharmacogenetically 
actionable opioids were prescribed at primary care visits mostly associated with either 
joint or lower back pain, but there were also multiple healthcare encounters for non-pain 
related conditions such as hypertension, diabetes, and depression. The patients in this 
group had between 1 to 11 visits and were prescribed between 4 to 19 different 
medications. Patient 07, a 62-year-old Black female, and Patient 11, a 54-year-old White 
female, both had a cytochrome P450 drug-drug interaction between diphenhydramine 
and tramadol. Diphenhydramine is a strong inhibitor of tramadol. The other non-pain-
related medications were most commonly prescribed to manage hyperlipidemia and 
hypertension. For example, Patient 15, a 60-year-old-Black woman consistently filled 
two medications for hyperlipidemia (atorvastatin and ezitimbe) and two medications for 
hypertension (amlodipine and hydrochlorothiazide) in addition to filling medications to 
treat her joint pain (tramadol, naproxen, and piroxicam).  
 Switching/Both. Three patients were placed in this group because they were 
prescribed a short-term supply of a pharmacogenetically actionable opioid that was 
followed shortly after (< 30 days) with a different opioid prescription while their emphasis 
of care was attributable to both pain and other comorbidities. This group included two 
women and a man. Two of the patients were Black, and one was Biracial/Hispanic. Two 
patients were CYP2D6 normal metabolizers and one patient was considered a poor 
metabolizer due to a drug-drug interaction.  
 Each patient in this group received a prescription for tramadol (n = 2) or codeine 
(n = 1) with a short supply (≤ 10 days). Soon after they filled the pharmacogenetically 
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actionable opioid, they received a new prescription for a different opioid. 
Oxycodone/acetaminophen was the new opioid prescribed for two of the patients and 
hydrocodone/acetaminophen was the new opioid prescribed to the third patient. For 
example, Patient 16, a 53-year-old Black woman, was prescribed an 8-day supply of 
tramadol 50 mg 1 tablet every 6 hours for pain as needed, and less than 1 month later 
was prescribed a 5-day supply of oxycodone/acetaminophen. This patient had a 
potential cytochrome P450 drug-drug interaction between the tramadol and fluoxetine. 
Fluoxetine is a strong inhibitor of tramadol, meaning the tramadol could potentially have 
reduced analgesic effects. Some patients received pain medications other than opioids, 
such as anti-inflammatory medications (NSAIDs). For example, Patient 03, a 51-year-old 
Hispanic woman, received prescriptions for tramadol, hydrocodone, and ibuprofen.  
 The switching opioid exposure pattern for these four patients occurred in the 
context of a medical emphasis on both pain and other comorbidities. They had 4 to 6 
health care visits over the 6-month period, and each received at least 10 medications for 
multiple indications. For example, Patient 13, a 51-year-old woman, was prescribed or 
refilled 24 different medications for indications that included pain, hypertension, 
hyperlipidemia, diabetes, depression, and others.  
 Sustained/Both. Two patients were placed in this group because they were 
prescribed pharmacogenetically actionable opioids for extended or continuous periods of 
time while having a medical emphasis of care on both pain and other comorbidities. Both 
of the patients in this group were White men, and one was a CYP2D6 normal 
metabolizer whereas the other was considered an intermediate metabolizer due to a 
drug-drug interaction.  
 Each patient in this group received a prescription for tramadol that they filled at 
least three times with a total supply of at least 60 days during the six-month period. For 
example, Patient 27, a 65-year-old White man, filled a prescription for a 30-day supply of 
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tramadol 50 mg to be taken once a day as needed for severe pain for three consecutive 
months. Patients in this group were prescribed few other pain medications, with a 
maximum of two additional medications for pain over the 6 month period. Patient 23, a 
52-year-old White male, had a P450 drug-drug interaction between tramadol and 
duloxetine, with duloxetine being a moderate inhibitor of tramadol. 
 The sustained opioid exposure pattern for these four patients occurred in the 
context of a medical emphasis on both pain and other comorbidities. These patients had 
6 to 10 healthcare encounters for pain-related conditions such as fibromyalgia, carpal 
tunnel syndrome, and joint pain, as well as for non-pain related conditions such as 
diabetes, depression, and hypertension.  They received between 7 and 20 medications 
for multiple indications. For example, Patient 23 was prescribed 20 different medications 
for conditions such as fibromyalgia, hypertension, hyperlipidemia, depression, anxiety, 
and a sleep disorder. This patient also had cytochrome P450 interaction between 
duloxetine and tramadol. Duloxetine is a moderate inhibitor of tramadol, meaning it can 
decrease the analgesic effects of tramadol. 
 Multiplex/Both. Three patients were placed in this group because they were 
prescribed a markedly complex regimen of pharmacogenetically actionable opioids while 
their medical emphasis of care was on both pain and other comorbidities. Two patients 
in this group were White men, whereas the other patient was a Black women. Two 
patients were normal metabolizers and one was an ultra-rapid metabolizer of the 
pharmacogenetically actionable opioids.  
 Two patients in this group received prescriptions for tramadol and one received 
prescriptions for codeine. The opioid patterns of these three patients represented some 
combination of the episodic or sustained patterns with some incremental dose 
adjustments. For example, Patient 17, a 54-year-old White man and ultra-rapid 
metabolizer, received a prescription for tramadol with an increasing dose. He was 
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instructed to take ½ tablet for 3 days, then ½ tablet twice a day for 3 days, then ½ tablet 
three times a day for 3 days, then ½ tablet every 6 hours as needed for pain. In addition, 
the pharmacogenetically actionable opioid was complemented by at least one additional 
opioid for all the patients. For example, Patient 09, a 30-year-old White male had 
received two prescriptions, approximately a month apart, for a 6-day supply of 
codeine/acetaminophen to be taken every 4 to 6 hours as needed for pain. In between 
those prescriptions, he was prescribed hydrocodone, and he was prescribed oxycodone 
at the same time as the second codeine prescription. Over the six month time frame 
these patients received 6 to 8 different prescriptions for pain, including the 
pharmacogenetically actionable opioids and other opioids (e.g., hydrocodone, 
oxycodone, fentanyl, hydromorphone), acetaminophen, anti-inflammatory medications 
(e.g., naproxen, ibuprofen), and other adjuvant medications (e.g., cyclobenzaprine, 
capsaicin cream). 
 The multiplex exposure pattern for these three patients occurred in the context of 
a medical emphasis on both pain and other comorbidities. They were treated for pain-
related conditions such as cervicalgia, lumbago, myalgia, and abdominal pain as well as 
a variety of non-pain-related conditions. All were being treated for depression and 
anxiety with medications such as amitriptyline, venlafaxine, trazadone, lorazepam, and 
alprazolam. The co-occurring psychiatric and pain conditions led to significant healthcare 
utilization as the patients in this group had 12 to 21 visits over the 6-month time period. 
Patient 09, for example, a 30-year old White male, had nine different healthcare 
encounters for depression, cervicalgia, and suicidal ideation within 27-days. Six of the 
visits were to the emergency department, two were to the primary clinic, and one was to 
a specialty clinic for depression. Overall, these patients received prescriptions for 
between 11 to 15 different medications. 
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Discussion 
The purpose of this study was to understand the nuances and complexity of 
exposure to tramadol and codeine - two opioid medications for which there are clear 
pharmacogenetically based guidelines. We found eight exposure patterns based on 
opioid prescription patterns and the medical emphasis (or focus) for which care was 
being sought. The patterns we uncovered show how the interactions between these 
salient factors unfolded over a six month period; thus, the typology yielded a more 
complex understanding of meaningful subgroups of individuals with differing patterns of 
exposure to pharmacogenetically actionable opioid medications than prior measures of 
medication exposure. Our study findings have generated information not previously 
described in the field and suggest that a shift is needed in the way medication exposure 
has been conceptualized. 
 Our findings confirm the importance of measuring exposure as a dynamic 
concept, rather than a dichotomous or single exposure variable as has been done in 
prior studies. The variations between the pharmacogenetically actionable opioid 
prescription patterns (e.g., singular, episodic, switching, sustained, and multiplex) 
highlight the nuances and multi-dimensional nature of medication exposure and the 
reason why exposure measures should capture changes over time.16 For example, the 
‘Episodic pattern’ involved varying periods of time over the six months in which the 
patients had interruptions in their opioid therapies. In contrast, the ‘Singular pattern’ 
included only one time limited prescription for the opioid and the ‘Sustained pattern’ 
involved prolonged periods of opioid use. Previous studies evaluating the effectiveness 
of pharmacogenetic testing have oversimplified medication exposure through 
dichotomous measures (e.g., yes/no an individual is taking a medication) or by 
medication count.8, 9, 11 For example, if medication exposure is captured at a single point 
in time, then continuous exposure or non-exposure to the drug would be assumed after 
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the baseline measurement. This would not account for any discontinuation or 
interruptions of opioid therapies as were noted in the Singular, Episodic, and Switching 
patterns. As evidenced by the patterns identified in this study, previously used measures 
fail to capture the dynamic and heterogeneous state of medication exposure and 
potentially lead to misclassification of the medication exposure.16 Thus, future 
medication exposure measures must go beyond dichotomous measures and capture the 
length and pattern of exposure to a pharmacogenetically actionable opioid. 
 The differences in medical emphasis of care between patterns raises concerns 
about the complexity of evaluating the clinical implementation of pharmacogenetic 
testing and its effects on opioid-related outcomes. The identified differences within the 
medical emphasis of care highlighted the importance of interactions among various 
medications used in complex treatment regimens, healthcare encounters, and reasons 
for seeking care. Pain and opioid use rarely occurs in isolation from other comorbidities 
or co-prescribed medications.45, 46 Largely, the subgroups had complicated medication 
regimens with evidence of polypharmacy. In certain instances, such as those patients 
with an emphasis of care on both pain and comorbidities, it could be difficult to 
distinguish what drug or drug-drug interaction is causing a particular adverse drug effect 
or medication non-response. Therefore, due to the heterogeneity and complexity of this 
population, it is likely that the benefits of pharmacogenetic testing may be difficult to fully 
capture as there are many confounding factors to be considered when evaluating clinical 
implementation of pharmacogenetic testing.  
 Additionally, a common method of predicting treatment outcomes of 
pharmacogenetically actionable opioids is through stratifying the population based on 
genotype-driven drug metabolizing phenotypes (i.e., poor, intermediate, extensive 
(normal), ultra-rapid metabolizers).47 The identified patterns show an alternative way to 
stratify or control for confounding factors in individuals receiving pharmacogenetically 
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actionable opioids. If we solely relied on the common use of the CYP2D6 genotype 
activity score to determine drug metabolizing phenotypes in this study, there would have 
been four resulting groups – ultra-rapid metabolizers (n = 2), normal metabolizers (n = 
25), intermediate metabolizers (n = 1), and poor metabolizers (n = 2). These data are 
consistent with population level frequency estimates in similar race/ethnic groups.3 
Although the poor metabolizers fell within the same pattern of exposure (Episodic/Both), 
the two ultra-rapid metabolizers fell within two different patterns (Episodic/Pain and 
Multiplex/Both) and the normal metabolizers fell within all eight, distinctly different 
patterns. In addition, the five cytochrome P450 drug-drug interactions of moderate to 
strong inhibitors of tramadol or codeine would not have been captured. The methods we 
used could be applied to better understand exposure to other non-opioid or 
pharmacogenetically actionable medications.  
 In general, this study also addressed a call to action to explore research 
strategies that aid in capturing heterogeneity across patients who use opioids and 
identifying meaningful subgroups that may respond differently to treatments.48 To our 
knowledge, no other studies have employed a qualitative, person-oriented approach to 
explore patterns of medication exposure with data coming from existing clinical and 
administrative data repositories. While the person-oriented approach cannot determine 
causation between medication exposure and clinical responses, this approach proved 
useful in identifying subgroups and comparing and contrasting salient factors of 
exposure. The identified patterns and subgroups can inform future studies that seek to 
develop a medication exposure measurement tool to account for confounding factors 
when evaluating clinical outcomes and costs of the implementation of pharmacogenetic 
testing, as well as in genomic association studies linking genes to opioid-induced side 
effects (e.g., constipation, nausea, or vomiting). Importantly, the subgroups can inform 
studies that seek to identify and tailor interventions in this population, thereby allowing 
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for more personalized health care and ultimately better pain management outcomes. For 
example, due to the identified complexities between the pharmacogenetically actionable 
opioid, polypharmacy, and extensive healthcare utilization, individuals falling within the 
Multiplex/Both pattern may benefit from personalized health coaching or coordinated 
pain management approaches across multiple providers. Individuals falling within the 
Singular/Pain pattern may require a significantly less intense intervention, such as a brief 
medication education intervention at or immediately after clinic discharge. 
 Our findings need to be interpreted in light of some limitations. While this 
qualitative, person-oriented approach identified subgroups that shared common patterns 
that reveal some of the intricacies and nuances of medication exposure and implications 
for pharmacogenetic testing, we recognize at the current stage of development of this 
typology we cannot make statements related to the prevalence of patients that would fall 
within each pattern or causal/predictive statements related to outcomes. With further 
development and validation, however, we believe a typology such as this could be used 
to tie group membership to clinical or economic outcomes such as medication response 
or costs of care. For example, Jonzon & Lindblad49 employed a person-oriented 
approach to identify subgroups of women who had exposure to sexual assault during 
their childhood. These investigators identified six different subgroups based on varying 
patterns of risk and protective factors (i.e., severity of child sexual abuse, severity of 
child physical abuse, coping, social support) and then determined that subgroup 
membership was significantly associated with adulthood outcomes such as 
psychological and psychosomatic symptoms and healthcare utilization. Similarly, with 
further research, we propose that groups that differ in medication exposure will likely 
have different outcomes related to pharmacogenetic testing and may require different 
strategies to ensure that the benefits of the testing are fully realized. A Singular/Pain 
group, for example, may be found to experience optimal analgesia following the use of 
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pharmacogenetic testing to select the most appropriate opioid therapy and may require 
minimal monitoring of pain response; whereas achieving optimal analgesia in the 
Multiplex/Both group may be more challenging as comorbidities and irregular health 
utilization would have to be considered in the monitoring of pain response and 
determining its relationship to the medication and dose that was selected based on 
pharmacogenetic testing.  
 There is limited generalizability beyond individuals who are prescribed either 
tramadol or codeine in the primary care setting at a safety-net healthcare system. Given 
the small sample size, further research is needed to further develop the typology in 
larger populations or those taking different pharmacogenetically actionable medications 
(e.g., amitriptyline). Furthermore, the retrospective nature and use of existing electronic 
health records also contributes to the limitations of this study. It was difficult to assess 
accuracy of the data (e.g., accuracy of ICD-9 codes as admit diagnosis) as well as 
whether certain data were missing within the electronic data sources. The way we 
assessed the inclusion criteria of “first prescription of record” assumed that all patients’ 
past healthcare records were captured within the Indiana Network for Patient Care. Also, 
we were only able to capture medication exposure through pharmacy records, thus we 
assumed that if a medication was prescribed and filled, the patient was actively taking 
that medication as prescribed. Ultimately, there was no true way of knowing whether the 
individuals were actually taking the opioid medication. In addition, electronic health 
records provide important clinical and administrative information, however, these 
sources lack information on patient perspectives.50 For example, data elements related 
to the intensity, duration, distress, and quality of an individual’s pain, along with their 
level of functioning, are not consistently documented or not captured within the 
electronic health record. Additionally, we were also limited in capturing potential 
medication side effects. Therefore, we were limited in capturing patient perspectives 
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related to their pain and response to the opioid medication. These will be important 
factors to include in future research. 
Conclusion 
We sought to expand the knowledge of medication exposure by employing an 
innovative, person-oriented approach to identify a typology of common patterns of 
exposure to pharmacogenetically actionable opioids in primary care. As a result, we 
identified eight typical patterns of medication exposure that highlighted the heterogeneity 
and variations among the sample prescribed these medications. Study findings advance 
the argument that medication exposure is not static, but rather dynamic and 
multidimensional. This is particularly meaningful when determining a medication 
exposure measure when evaluating the utility of pharmacogenetic testing and its impact 
on selecting and dosing pharmacogenetically actionable opioids. Additionally, the 
patterns serve as a means to stratify individuals into meaningful subgroups of 
medication exposure. Therefore, these patterns can inform future studies that seek to 
personalize care through identifying and tailoring interventions in individuals prescribed 
pharmacogenetically actionable opioids. Finally, our approach could be applied to other 
medications and other patients groups.  
 
 
   
 
7
6
 
Table 3-1.  
Typology of Exposure to Pharmacogenetically Actionable Opioids 
 Pharmacogenetically Actionable Opioid Prescription Pattern1 
Singular Episodic Switching Sustained Multiplex 
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Pain 
One, time-limited 
prescription for the 
PGxA opioid and 
reasons for care 
are largely 
attributed to pain-
related conditions. 
Intermittent, or 
discontinuous, 
prescriptions for 
PGxA opioids and 
reasons for care 
are largely 
attributed to pain-
related conditions. 
   
 
 
 
Comorbidities 
One, time-limited 
prescription for the 
PGxA opioid and 
reasons for care 
are largely 
attributed to non-
pain related 
illnesses or 
diseases. 
    
 
 
 
Both  
 
One, time-limited 
prescription for a 
PGxA opioid and 
reasons for care 
largely attributed 
to both pain and 
other co-occurring 
illnesses or 
diseases.  
Intermittent, or 
discontinuous, 
prescriptions for 
PGxA opioids and 
reasons for care 
largely attributed to 
both pain and other 
co-occurring 
illnesses or 
disease. 
Short-term supply 
of PGxA opioid 
followed by a 
new/different opioid 
and reasons for 
care largely 
attributed to both 
pain and other co-
occurring illnesses 
or diseases. 
Extended periods 
of uninterrupted 
prescriptions or 
refills of the PGxA 
opioid and reasons 
for care largely 
attributed to both 
pain and other co-
occurring illnesses 
or diseases. 
Combination of 
PGxA opioid 
patterns and 
reasons for care 
largely attributed 
to both pain and 
other co-
occurring 
illnesses or 
diseases. 
Table continues 
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PGxA: Pharmacogenetically actionable. 
1 Pharmacogenetically Actionable Opioid Prescription Pattern was determined from prescription data including dose, timing   
  of fills/refills, and supply amounts over the 6-month time period.   
2 Medication Emphasis of Care was determined from patterns in data representing medical histories, type and indication for  
  all medications prescribed, clinical responses, and type and reasons for healthcare encounters over the 6-month time   
  period.   
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Table 3-2.  
Sample Characteristics by Exposure Pattern 
 Singular/ 
Pain 
Singular/ 
Comorbid 
Singular/ 
Both 
Episodic/ 
Pain 
Episodic/ 
Both 
Switching/
Both 
Sustained/ 
Both 
Multiplex/ 
Both 
Total 
N 2 4 3 3 10 3 2 3 30 
Age (years) 
Mean  
(SD)  
Range 
 
57.5  
(4.9) 
54-61 
 
52.8  
(12.8) 
34-62 
 
47  
(12.1) 
40-61 
 
47  
(3.6) 
44-51 
 
51  
(11.9) 
23-62 
 
49.3  
(4.7) 
44-53 
 
58.5  
(9.2) 
52-65 
 
48.3 
(16.3) 
30-61 
 
50.9  
(10.4) 
23-65 
Sex n (%) 
Male  
Female 
 
2 (100) 
--- 
 
4 (100) 
--- 
 
1 (33.3) 
2 (66.7) 
 
1 (33.3) 
2 (66.7) 
 
1 (10) 
9 (90) 
 
1 (33.3) 
2 (66.7) 
 
2 (100) 
--- 
 
2 (66.7) 
1 (33.3) 
 
14 (46.7) 
16 (53.3) 
Race n (%) 
White 
Black 
Biracial 
 
2 (100) 
--- 
--- 
 
2 (50) 
2 (50) 
--- 
 
3 (100) 
--- 
--- 
 
1 (33.3) 
2 (66.7) 
--- 
 
6 (60) 
4 (40) 
--- 
 
--- 
2 (66.7) 
1 (33.3) 
 
2 (100) 
--- 
--- 
 
2 (66.7) 
1 (33.3) 
--- 
 
18 (60) 
11 (36.7) 
1 (3.3) 
Ethnicity n (%) 
Not Hispanic 
Hispanic 
Unknown 
 
2 (100) 
--- 
--- 
 
3 (75) 
--- 
1 (25) 
 
3 (100) 
--- 
--- 
 
2 (66.7) 
--- 
1 (33.3) 
 
9 (90) 
--- 
1 (10) 
 
2 (66.7) 
1 (33.3) 
--- 
 
2 (100) 
--- 
--- 
 
3 (100) 
--- 
--- 
 
26 (86.7) 
1 (3.3) 
3 (10) 
PGxA Opioid  
n (%) 
Tramadol 
Codeine 
 
 
2 (100) 
--- 
 
 
3 (75) 
1 (25) 
 
 
2 (66.7) 
1 (33.3) 
 
 
3 (100) 
--- 
 
 
8 (80) 
2 (20) 
 
 
2 (66.7) 
1 (33.3) 
 
 
2 (100) 
--- 
 
 
2 (66.7) 
1 (33.3) 
 
 
24 (80) 
6 (20) 
SD = standard deviation; PGxA = Pharmacogenetically Actionable 
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Table 3-3.  
CYP2D6 Activity Score, Drug-Drug Interactions, and Drug Metabolizing Phenotype by Exposure Pattern 
 Singular/ 
Pain 
Singular/ 
Comorbid 
Singular/ 
Both 
Episodic/ 
Pain 
Episodic/ 
Both 
Switching/
Both 
Sustained/ 
Both 
Multiplex/ 
Both 
Total 
N 2 4 3 3 10 3 2 3 30 
CYP2D6 
Genotype 
Activity Score  
0 
0.5 
1.0 
1.5-2 
>2 
 
 
 
--- 
1 (50) 
--- 
1 (50) 
--- 
 
 
 
--- 
--- 
2 (50) 
2 (50) 
--- 
 
 
 
--- 
--- 
--- 
3 (100) 
--- 
 
 
 
--- 
--- 
--- 
2 (66.7) 
1 (33.3) 
 
 
 
2 (20) 
--- 
3 (30) 
5 (50) 
--- 
 
 
 
--- 
--- 
2 (66.7) 
1 (33.3) 
--- 
 
 
 
--- 
--- 
1 (50) 
1 (50) 
--- 
 
 
 
--- 
--- 
2 (66.7) 
--- 
1 (33.3) 
 
 
 
2 (6.7) 
1 (3.3) 
10 (33.3) 
15 (50) 
2 (6.7) 
P450 DDI with 
Opioid 
None 
Moderate 
Strong 
 
 
2 (100) 
--- 
--- 
 
 
3 (75) 
--- 
1 (25) 
 
 
3 (100) 
--- 
--- 
 
 
3 (100) 
--- 
--- 
 
 
8 (80) 
--- 
2 (20) 
 
 
2 (66.7) 
--- 
1 (33.3) 
 
 
1 (50) 
1 (50) 
--- 
 
 
3 (100) 
--- 
--- 
 
 
25 (83.3) 
1 (3.3) 
4 (13.3) 
Final 
Phenotypes 
         
UM 
NM 
IM 
PM 
--- 
1 (50) 
1 (50) 
--- 
--- 
3 (75) 
--- 
1 (25) 
--- 
3 (100) 
--- 
--- 
1 (33.3) 
2 (66.7) 
--- 
--- 
--- 
6 (60) 
--- 
4 (40)* 
--- 
2 (66.7) 
--- 
1 (33.3) 
--- 
1 (50) 
1 (50) 
--- 
1 (33.3) 
2 (66.7) 
--- 
--- 
2 (6.7) 
20 (66.7) 
2 (6.7) 
6 (20) 
Data reported as n (%). 
PGxA = Pharmacogenetically Actionable; DDI: Drug-drug interaction; PM = Poor Metabolizer; IM = Intermediate Metabolizer; 
NM = Normal Metabolizer; UM = Ultra-rapid Metabolizer 
*The two patients who had a CYP2D6 genotype activity score of 0 were not the same patients who had a DDI with a strong 
inhibitor. 
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Table 3-4. 
Case Exemplars by Exposure Pattern 
Pattern Exemplar 
 
 
Singular/Pain 
Patient 26 was a 61-year-old White male and CYP2D6 normal metabolizer. He had a one, time 
limited prescription for tramadol and had a history of cervicalgia. He sought care at the primary 
care clinic for this condition and was prescribed tramadol 50 mg to be taken at night for severe 
pain. The pain intensity documented at this visit was 5/10. In addition to the new tramadol 
prescription, 2 other medications for pain were prescribed at this visit – naproxen and 
cyclobenzaprine. All three prescriptions were filled. Over the 6 month period, there were no 
additional healthcare encounters or medications prescribed or filled.  
 
 
 
 
 
Singular/Comorbidities 
Patient 19 was a 34-year-old Black male and CYP2D6 normal metabolizer. He had a one, time-
limited prescription for codeine and suffered from a number of comorbidities, including 
HIV/AIDS, Hepatitis B and C, seborrheic dermatitis, constipation, and back and shoulder pain. 
He sought care at the primary care clinic for HIV disease and back ache. At this visit he rated 
his pain intensity as a 10/10. He was prescribed a 30 day supply of codeine/acetaminophen to 
be taken as needed for pain. In addition, he was also prescribed bupropion and conjugated 
estrogen. All three of these medications were filled, and other than the mentioned codeine 
prescription, there was no evidence of any pain medications prescribed or filled over the 6 
month period; however, his medication regimen consisted of 9 other medications that were 
regularly filled. In the same time period, there were a total of 2 primary care visits and 3 
specialty clinic visits for diagnoses other than pain (e.g., HIV). There was one cytochrome P450 
drug-drug interaction between bupropion (strong inhibitor) and codeine/acetaminophen. This 
interaction led to Patient 19’s phenotype change from a CYP2D6 normal metabolizer to a poor 
metabolizer. 
 Table continues 
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Singular/Both 
Patient 30 was a 61-year-old White female and CYP2D6 normal metabolizer had multiple 
comorbidities such as coronary artery disease, asthma, esophageal reflux, depression, and a 
number of pain conditions (headache, neuralgia, abdominal pain). She had a one, time limited 
prescription for 15-day supply for tramadol prescribed at a primary care visit for esophageal 
reflux, H. pylori infection, headache and neuralgia. Also at this visit she was prescribed 8 
additional medications such as prednisone, amitriptyline, esomeprazole, 2 asthma medications, 
and 2 anti-infective medications. All were filled the day after the primary care visit. Following that 
visit there were multiple additional healthcare encounters for both pain and non-pain-related 
conditions, including 3 visits to the primary care clinic, 5 visits to specialty care clinics, and 1 
emergency department visit. Despite the frequent healthcare encounters, the only additional 
prescription provided was for esomeprazole and there were no new prescriptions for tramadol or 
any other pain medications.  
 
 
 
 
Episodic/Pain 
Patient 29, a 44-year-old White male and CYP2D normal metabolizer, had a history of knee 
pain and hypertension. He sought care at the primary care clinic for joint pain in his left leg. At 
this visit he rated his pain intensity as an 8/10 and was prescribed a short-term (7-day) supply of 
tramadol to be taken every 6 hours as needed for pain. Additionally, naproxen to be taken twice 
a day. Both of these prescriptions were filled, along with a prescription for lisinopril. In the 
following 6-months, there were an additional 3 primary care visits and 1 specialty clinic visit – all 
for joint pain/osteoarthritis. Furthermore, there were 2 documented pain intensities of 7 and 
10/10. Three months following the original tramadol prescription, there was a new order for a 
15-day supply of tramadol to be taken every 6 hours as needed for pain. Also at this time there 
was evidence that the naproxen prescription was refilled.  
 Table continues 
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Episodic/Both 
Patient 04 was a 57-year-old Black female and CYP2D6 normal metabolizer. She was 
prescribed codeine/acetaminophen at a primary care visit for depressive disorder, hypertension, 
and joint pain. At this visit the reported pain intensity was documented as 7/10. Also prescribed 
were 1 antihypertensive medication (hydrochlorothiazide) and 2 psychiatric medications 
(desvenlafaxine and risperidone). All medications were filled, with a 10 day supply of codeine 
being dispensed. Approximately one month following the initial visit, there was another primary 
care visit with a documented pain intensity of 6/10, a specialty clinic visit for venereal disease, 
and 2 inpatient hospitalizations lasting longer than 1 month for cervicalgia. One month following 
discharge from the hospital, there was a primary care visit for Herpes Zoster, with a pain rating 
of 10/10 was reported. Subsequently, a 10 day supply of codeine, along with an antiviral, was 
prescribed and filled. In total, there were 8 different medications part of the medication regimen 
and a total of 6 healthcare encounters.  
 
 
 
Switching/Both 
Patient 03, a 44-year-old Black male and CYP2D6 normal metabolizer, was prescribed 
codeine/acetaminophen, to be taken as needed for pain, at a primary care visit for gout and 
hypertension. At this visit, a pain intensity of 10/10 was recorded. The codeine prescription was 
filled with a 3-day. Less than a week later, the patient sought care in the emergency department 
for foot pain, and was subsequently prescribed a 5 day supply of oxycodone/acetaminophen. 
Three weeks later, the patient returned to the primary care clinic with a pain intensity of 8/10 
and a 5 day supply of oxycodone/acetaminophen was prescribed and filled. In addition to these 
opioids, there were 8 different medications prescribed and consistently filled to manage 
conditions such as hypertension, heart failure, and gout. 
 Table continues 
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Sustained/Both 
Patient 23, a 52-year-old White male who was a CYP2D6 normal metabolizer, had a history of 
fibromyalgia, depression, hypertension, and coronary artery disease who was prescribed 
tramadol 50 mg to be taken as needed for pain, at a primary care visit for coronary 
atherosclerosis. In addition, multiple other medications were prescribed, resulting in 10 different 
medications part of the medication regimen. The 20 day supply of tramadol was filled/refilled a 
total of 4 times. After the initial visit, there were a total of 2 additional primary care visits and 7 
specialty clinic visits for diagnoses such as abdominal pain, neuralgia, major depression, 
anxiety, and hypertension. Overall, there were a total of 20 different medications for multiple 
chronic conditions as part of the medication regimen over the 6 month period. There were also 
four different potential cytochrome P450 drug-drug interactions, one of which was between 
duloxetine (moderate inhibitor) and tramadol. This interaction led to Patient 23’s phenotype 
change from a CYP2D6 normal metabolizer to an intermediate metabolizer. The other drug-drug 
interactions were between duloxetine (inhibitor) and metoprolol, omeprazole (inhibitor) and 
clopidogrel, and esomeprazole (inhibitor) and clopidogrel. 
 Table continues 
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Multiplex/Both 
Patient 08, a 61-year-old Black female who is a CYP2D6 normal metabolizer, was prescribed 
tramadol 50 mg to be taken as needed for pain, at a primary care visit for hyperparathyroid, 
hypertension, and osteoarthritis. At this visit there was a documented pain intensity of 8/10 and 
other medications prescribed included lorazepam and cyclobenzaprine. All 3 medications were 
filled. The tramadol prescription was refilled with a 17 day supply approximately 1 month after 
the original fill date. 10 days after the refill, there was a visit to a specialty clinic for polyarthritis 
and new prescription for a 28 day supply hydrocodone was provided. Less than a week later, 
the patient returned to the primary clinic for osteoarthritis and a 7 day supply for hydromorphone 
was prescribed for fibromyalgia. There were 2 more prescriptions for 15 day supplies of 
hydromorphone provided a month apart in the following 2 months. Less than a month after the 
third prescription for hydromorphone, and approximately 3 months following the last tramadol 
refill, there was a new prescription written for tramadol. This prescription was filled and then 
refilled 3 weeks later. In addition to the opioids, this patient had evidence of filling prescriptions 
for an anti-inflammatory (indomethacin), muscle relaxant (cyclobenzaprine), antirheumatic 
(leflunomide), and a benzodiazepine (lorazepam) medications over the 6 months. Overall, this 
patient’s medication regimen consisted of 11 different medications, 6 of which were for pain. 
There were also 12 healthcare encounters – 6 visits to the primary care clinic, all for pain-
related conditions, and 6 to specialty clinics, which only 3 of those visits were related to pain. 
Additionally, during 4 of the visits there were documented pain intensity ratings ranging from 8-
9/10. 
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CHAPTER 4 
 This chapter presents the results of the manuscript, “Comorbidities, Healthcare 
Utilization, and Medication Regimens in Underserved Primary Care Patients Prescribed 
Pharmacogenetically Actionable Opioids.” 
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Abstract 
 Despite the promise of pharmacogenetic testing, significant challenges for 
evaluating the outcomes related to its implementation exist, including the complexity of 
patients’ clinical profiles. The purpose of this study was to describe the context in which 
pharmacogenetically actionable opioids (codeine and tramadol) are prescribed, including 
patients’ comorbidities, healthcare utilization, and medication regimens, in a large safety-
net health system. We used 6 months of electronic health record and CYP2D6 
pharmacogenetic genotype data from 30 adult patients to evaluate their number and 
type of comorbidities, healthcare encounters, and medications prescribed. Findings 
showed that patients had multiple comorbidities, with all patients experiencing 2 or more 
comorbidities and 57% (n = 17) experiencing 5 or more. On average, patients had 6.9 
healthcare encounters and were prescribed 10 different medications over a 6-month 
time period. Five patients (17%) had potential drug interactions that could have affected 
their CYP2D6 drug metabolizing status. Findings indicated that complex medical 
histories, extensive healthcare utilization, and the number of co-prescribed medications 
in patients prescribed pharmacogenetically actionable opioids could potentially confound 
the desired clinical and economic benefits of pharmacogenetic testing. Therefore, future 
research and clinical implementation of pharmacogenetic testing to guide opioid 
therapies must control or account for these important factors. 
 
Keywords: Pharmacogenomics, pharmacogenetic testing, clinical implementation, 
opioid, pain management, comorbidities, healthcare utilization, polypharmacy 
  
 91 
 
Comorbidities, Healthcare Utilization, and Medication Regimens in Underserved 
Primary Care Patients Prescribed Pharmacogenetically Actionable Opioids 
 Pharmacogenetic testing has the potential to improve pain management through 
addressing wide interindividual variations in responses to pharmacogenetically 
actionable opioids such as codeine and tramadol.1 Pharmacogenetic testing aids in the 
identification of individual genetic variations that affect drug disposition and response 
and thus could improve clinical and economic outcomes by improving medication 
responses and decreasing adverse drug effects.2-4 Pharmacogenetically actionable 
medications are those for which there are evidence-based guidelines to guide drug or 
dosage changes based on pharmacogenetic test results. 
 Despite the promise of pharmacogenetic testing, the complexity of patients’ 
clinical profiles can confound its desired clinical and economic benefits.3, 5, 6 Three 
patient clinical profile factors likely to influence the outcomes of pharmacogenetic testing 
are patient comorbidities, healthcare utilization, and medication regimens. Comorbidities 
are common since pain rarely occurs in isolation from other conditions. Multiple pain and 
non-pain comorbidities can lead to significant variability in clinical responses and 
complicate healthcare utilization and costs of care.7 In addition, patients who experience 
pain are often treated by a number of providers during multiple healthcare encounters 
and prescribed several different medications to manage their pain and other comorbid 
conditions.8 Furthermore, polypharmacy, or the concurrent taking of multiple 
medications, may increase the potential for adverse drug effects or medication non-
response as a result of known or unknown drug-drug interactions.9 Although a better 
understanding of these three factors could enhance the effectiveness of 
pharmacogenetic testing used to improve pain management10, these factors are not 
currently considered in clinical guidelines for pharmacogenetic testing11 and no studies 
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to date have described these factors in a group of patients being prescribed 
pharmacogenetically actionable opioids. 
The goal of this study was to describe in detail the comorbidities, healthcare 
utilization, and medication regimens of patients who had been prescribed tramadol or 
codeine in a primary care clinic within a large safety-net health system. The primary care 
clinics provided an optimal setting for the study as they served an underserved 
population with complex clinical profiles that are likely to complicate the implementation 
of pharmacogenetic testing which is underway within the setting. 
Methods 
Design & Setting 
 This study was a retrospective, secondary analysis of 6-months of de-identified 
data from electronic health records and banked DNA specimens from a randomly 
selected sample of patients who were newly prescribed a pharmacogenetically 
actionable opioid in a primary care clinic within a large safety-net health system. The 
data were collected as part of a study that sought to identify a typology of meaningful 
subgroups that shared common patterns of exposure to these medications.12 The safety-
net health system primarily serves low-income and vulnerable patients and, at the time 
of this study, was in the process of implementing widespread pharmacogenetic testing 
for 30 different target medications.13 This system has robust data repositories that 
allowed for capturing information such as medical histories, medication records and 
healthcare utilization from patients’ comprehensive health records and for linking 
electronic health records to DNA samples. Due to the de-identified nature of this study, it 
was deemed non-human subjects research by the Indiana University Office of Human 
Subjects Research. 
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Sample 
 The sample included 30 patient records randomly selected from a pool of 118 
patients who met the following inclusion criteria: 1) part of a managed care program for 
individuals falling at or below 200 percent of the federal poverty level, 2) first prescription 
of record for codeine or tramadol in at least one of the primary care clinics within the 
large safety-net health system, 3) had a banked blood sample, 4) age 21 and older, and 
5) had no documentation of substance abuse in the electronic health record. A ‘first 
prescription of record’ was defined as either codeine or tramadol being prescribed 
between January 1, 2010 and December 31, 2014 and no information in the patient’s 
record that indicated that either medication had been previously prescribed. 
Data Sources & Procedures 
 Six months of electronic health record data for each patient were obtained from 
comprehensive data repositories. The six-month time period started with the date of the 
new prescription for either codeine or tramadol and ended six months later.  Data were 
accessed, extracted, and de-identified by a trained data analyst. The main repository 
where data originated was the Indiana Network for Patient Care, which is a large, multi-
institutional information exchange that captures electronic health record data from more 
than 25,000 individual providers, 106 hospitals, and 110 clinics and surgery centers.14 
The repository allows for capturing information about patients’ healthcare encounters 
across multiple clinics and health systems and information about medication orders 
and/or dispensing data from the safety-net health system, other health systems, and 
outpatient pharmacies within the region where this study was conducted. Other sources 
included clinical and administrative data repositories associated with the managed care 
program and safety-net health system. Furthermore, the electronic health records were 
linked to banked DNA specimens obtained from the biobank. All data were de-identified 
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by the data analyst through existing processes prior to being released to the research 
team.    
 Patient characteristics. Demographic characteristics at the time of the new 
prescription for the pharmacogenetically actionable opioid, including age, gender, and 
race, were extracted from electronic health records. The time between the first 
encounter within the safety-net health system and the first prescription for the 
pharmacogenetically actionable opioid was calculated as an indicator of how long 
patients had been followed within the health system.  
Comorbidities. The comorbidities experienced by the patients during the six-
month time period were identified by the International Classification of Diseases – 9th 
Revision (ICD-9) codes recorded as part of the problem or diagnoses list and/or chief 
complaint with each healthcare encounter. The ICD-9 codes were aggregated by pain 
and non-pain diagnoses and descriptive analysis (frequencies) were used to determine 
the occurrences of each comorbid condition.  
 Healthcare utilization. Healthcare encounters occurring within six months 
following the new opioid prescription were determined through a de-identified location 
number indicating where a service was provided. The encounters were classified as 
primary care clinic, specialty care clinic, emergency department, or inpatient 
hospitalization. Clinic sites classified as specialty care included, but were not limited to, 
cardiology, hematology, neurology, mental health, urology, and orthopedics. Each 
healthcare encounter was linked to a chief complaint or admit diagnosis through an ICD-
9 code(s) so that the reason of the visit could be determined. Mean number and 
frequencies for total visits, as well as pain-related visits, were calculated for each type of 
clinic (i.e., primary care, specialty care, emergency). 
 Medication regimens. The medication regimen prescribed for each patient was 
identified through data elements including medication name, dose, dose frequency, 
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route, administration instructions, and fill or refill dates. The mean number and range of 
medications prescribed per patient, including the pharmacogenetically actionable 
opioids, was determined over the six month time period. Because widespread 
implementation of pharmacogenetic testing for 30 different target medications was being 
implemented within the safety-net health system13, we categorized medications as 
pharmacogenetically actionable or other. We also classified type of medication based on 
its indication and reported frequency of patients taking each type. Furthermore, for those 
patients who were prescribed a certain medication type (e.g., pain medications, cardiac 
medications, psychiatric medications, etc.), the mean number and range of medications 
for that type was determined. 
 CYP2D6 drug interactions and phenotypes. We also reviewed each patient’s 
medication regimen to determine if any potential cytochrome P450 drug-drug 
interactions (DDI) that would alter the CYP2D6 enzyme activity were present.15 We 
noted a potential DDI was present if two medications had known P450 interactions and 
that the supply amount dispensed for each medication overlapped. For example, if a 30-
day supply of tramadol was dispensed 10 days following a 60-day supply of fluoxetine 
being dispensed, we assumed that these two medications would be taken concurrently 
and coded these data as DDI present.    
 Data from the identified drug-drug interactions were then used to calculate the 
final CYP2D6 enzyme activity score and CYP2D6 drug metabolizing phenotype. The 
activity score is used to identify the drug metabolizing phenotype classification and is 
determined by the sum of values assigned to each CYP2D6 allele making up the 
diplotype.11 Therefore, we completed CYP2D6 genotype on the banked DNA specimens 
for all patients in this study. The genotyping was performed for the CYP2D6 star alleles 
*2, *3, *4, *5, *6, *9, *10, *17, *29, and *41 using the QuantStudio (Thermo Fisher 
Scientific, Inc., Grand Island, NY) and following the manufacturer’s instructions of the 
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Taqman Genotyping Assays (Applied Biosystems, Inc., Foster City, CA). These star 
alleles were chosen because they have common variants that influence both codeine 
drug disposition and response, as well as their frequencies in the Caucasian, African 
and their descendant populations.16 We completed quality controls for each sample 
batch and repeated assays for 20% of samples. There was a genotyping sample call 
rate of 99.4%. The genotype results were then used to calculate the CYP2D6 enzyme 
activity score.11 This activity score was then adjusted based on the occurrence of any 
drug-drug interactions. For drug-drug interactions with strong inhibitors of the opioid, the 
final activity score of 0 was assigned. For drug-drug interactions with moderate inhibitors 
of the opioid, the CYP2D6 enzyme activity score was multiplied by 0.5 to identify the 
final activity score.17 Consequently, the drug metabolizing phenotype for each patient 
was then determined from the final activity score.11  
Results 
  The sample consisted of 30 adults, nearly evenly divided in terms of gender 
(Table 1), and of whom 40% were Black or Biracial. Ages ranged from 23 to 65 years, 
with a mean of 50.9 years (SD = 10.4). Of the pharmacogenetically actionable opioids, 
24 patients were prescribed tramadol, and six were prescribed codeine. The time 
between the first encounter within the safety-net health system and the first prescription 
for either tramadol or codeine was a mean of 14.5 years (SD = 10.9; range = 0 – 34.7 
years; median = 13.8 years). The time between the pharmacogenetically actionable 
opioid prescription and the medication being dispensed was a mean of 1.6 days. 
Comorbidities 
 The patients in the sample typically experienced multiple comorbidities. Table 4-1 
presents the 19 most frequently occurring comorbidities. In terms of non-pain 
comorbidities, 63% of the sample was diagnosed with hypertension and 50% were 
diagnosed with depression. In terms of pain-related comorbidities, 63% experienced joint 
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pain/osteoarthritis. Many of the patients were diagnosed with multiple co-occurring 
painful and non-pain-related comorbidities (Figure 4-1). All of the patients (100%) had at 
least two or more comorbidities, and 17 (57%) had five or more. Furthermore, 23 
patients (77%) had two or more non-pain comorbidities and 22 patients (73%) had two 
or more documented pain-related comorbidities. 
Healthcare Utilization 
 The patients in this sample had frequent healthcare utilization over the 6-month 
period (Table 4-2). The total number of healthcare encounters ranged from 1 to 21 
different visits, with an average of 6.9 healthcare encounters per patient, or slightly more 
than one per month on average. Of these visits, there was an average of 3.7 visits to 
primary care clinics, 2.7 visits to specialty clinics, and 0.5 visits to the emergency 
department. Visits attributed to pain accounted for less than half of the healthcare visits, 
however, pain complaints accounted for 86% of emergency department visits. One 
patient had inpatient admissions of 18 and 24 days for cervicalgia (not reflected in Table 
4-2).  
Medication Regimens 
 The patients in the sample received an average of 10 different medication 
prescriptions with a range of 2 to 24 medication prescriptions over the 6-month time 
period indicating significant polypharmacy within the sample (Table 4-3). A mean of 3.0 
different pain medications were prescribed per patient, of which one was either codeine 
or tramadol per inclusion criteria (Table 4-3). Furthermore, medications for 
cardiovascular conditions were prescribed for 77% (n = 23) of the sample; these patients 
were prescribed an average of 2.9 medications for indications such as hypertension, 
dyslipidemia, and anticoagulation. In addition, 60% (n = 18) of the sample were 
prescribed medications for psychiatric problems such as depression or anxiety.  
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Figure 4-2 highlights the total number of medications per patient as well as the 
total number of medications identified as pharmacogenetically actionable as part of the 
widespread implementation of pharmacogenetic testing within the safety-net health 
system. Fifty percent (n = 15) of patients were only taking one pharmacogenetically 
actionable medication, which was either codeine or tramadol. Moreover, 30% (n = 9) of 
the patients were taking two different pharmacogenetically actionable medications, 13%   
(n = 4) were taking three different pharmacogenetically actionable medications, and 
nearly 7% (n = 2) were taking five different pharmacogenetically actionable medications.  
 Genotype and medications affected CYP2D6 metabolizer status. The 
pharmacogenetic genotyping identified most patients as normal metabolizers (n = 25). 
The five remaining patients had genetic variations affecting their CYP2D6 drug 
metabolizing status, making them CYP2D6 poor metabolizers (n = 2), intermediate 
metabolizers (n = 1), or ultra-rapid metabolizers (n = 2). These data are consistent with 
population level frequency estimates in similar race/ethnic groups.11 However, after 
reviewing patients’ medication regimens, five (17%) additional patients had potential 
CYP2D6 drug-drug interactions with either codeine or tramadol (Table 4-4). Additionally, 
in two patients there were potential CYP2D6 drug-drug interactions involving metoprolol. 
Thus, a total of eight patients (27%) could be classified as CYP2D6 poor (n = 6) or 
intermediate metabolizers (n = 2) based on the totality of contextual information 
available.  
Discussion 
 The goal of implementing pharmacogenetic testing in clinical practice is to help 
address wide interindividual variations in response to medication therapies such as 
tramadol and codeine. Ideally, this testing would lead to improved clinical and economic 
outcomes through optimal analgesia and avoidance of adverse drug effects and 
medication non-response. However, a number of factors that comprise patients’ clinical 
 99 
 
profiles can confound the desired outcomes of pharmacogenetic testing.3, 10 To our 
knowledge, our findings are a first to provide a detailed description of the comorbidities, 
healthcare utilization, and medication regimens that might influence the outcomes of 
pharmacogenetic testing in an underserved population prescribed pharmacogenetically 
actionable opioids. Our findings begin to quantify the contextual complexity of this 
patient population.  
 Our findings clearly indicate that the patients in this sample had complex 
comorbidities and healthcare utilization. All patients had at least two pain and/or non-
pain comorbidities, and 57% had five or more. These rates are significantly higher than 
have been reported elsewhere. The National Council on Aging18, for example, reports 
that 80% of older adults have at least one chronic condition and 68% have two or more. 
In addition, most of the patients in our study had significant healthcare utilization. Our 
finding that the participants had an average of 6.9 healthcare encounters in six months is 
more than four times the average of 3.01 outpatient clinic visits per patient each year as 
reported by Ashman et al.19 Our finding of significant polypharmacy exceeds national 
data where an average of 4 unique medications are prescribed per person every year20 
and is comparable to findings from other studies with patients seeking treatment for 
pain.7, 21 For example, Davis and colleagues7 studied 1,211,483 adults in 23 different 
pain cohorts (e.g., HIV-associated pain, cancer pain, migraine) and found an average of 
3.5 pain medications prescribed during the one year study period. 
 Polypharmacy can also increase the potential for undesirable consequences.8 
Five different patients were identified with potential CYP2D6 drug-drug interactions with 
the pharmacogenetically actionable opioids. These interactions occurred with either a 
strong or moderate inhibitor of the CYP2D6 enzyme, which would likely result in no or 
decreased analgesic effects from tramadol or codeine.11 These patients’ responses to 
the pharmacogenetically actionable opioid would be similar to those responses of the 
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two patients with two non-functional CYP2D6 alleles; thus CYP2D6 drug-drug 
interactions have the ability to confound the associations between variants identified 
through pharmacogenetic testing and medication responses. These data underscore the 
importance of multi-drug, multi-gene approaches to implementing pharmacogenetic 
testing to fully address patients’ needs.  
Implications for Research 
In populations with complex clinical profiles, a number of methodological issues 
need to be considered to study the outcomes of pharmacogenetic testing. For example, 
to determine if such testing could decrease healthcare utilization by facilitating optimal 
analgesia, it would be essential to distinguish between visits associated with pain and 
the pharmacogenetically actionable medication(s) and visits associated with other 
symptom(s) or disease(s). The finding in our study that less than half of visits to primary 
care and specialty care clinics were attributed to pain suggests that evaluating the 
aggregation of all visits over a specified period of time will not be sufficient. For example, 
one patient had a total of 6 healthcare encounters over the six month period of time, with 
four of the visits to manage uncontrolled hypertension and two visits to address and 
manage pain. For this patient, the aggregate total of 6 healthcare encounters would not 
be the best indicator of healthcare encounters to determine the effects of 
pharmacogenetic testing on healthcare utilization.  
Similarly, consideration of the effects of polypharmacy on outcomes of 
pharmacogenetic testing would need to be considered in research studies. Patients in 
our sample were prescribed on average 10 different medications and, of these 
medications, an average of 3.0 different medications were prescribed for pain. While 
multimodal therapy is considered a best practice for managing pain22, 23, this approach 
can complicate evaluation of potential adverse effects and medication responses which 
are desired outcomes of pharmacogenetic testing. For example, a patient may 
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experience adequate analgesia with an anti-inflammatory medication and 
pharmacogenetically actionable opioid, but researchers would need to determine the 
medication responses, including side effects, that are attributable to the opioid alone. 
The influence of multiple pain-related conditions with different etiologies on the testing 
outcomes would also need to be considered. Given the frequency of co-occurring pain 
conditions, for example, a pharmacogenetically actionable opioid may improve pain 
related to a musculoskeletal injury, for example, but not necessarily neuropathic pain, 
which may continue to lead to high healthcare utilization and costs.  
Studies of pharmacogenetic testing thus will need to control or account for the 
confounding effects of clinical profile factors through more complex research designs 
(i.e., randomized controlled trials) and/or stratification methods (i.e., propensity score 
matching).3, 24 These strategies would also require large sample sizes to fully realize the 
benefits of pharmacogenetic testing in this population.      
Future research could also evaluate the use of multi-component interventions 
that partner pharmacogenetic testing with other components. Adding care coordination, 
medication adherence interventions, and family education and support could have a 
greater combined impact on clinical and economic outcomes than pharmacogenetic 
testing alone. Developing and testing such intervention packages would require the 
expertise of multiple disciplines, including nursing with their expertise in side 
effect/symptom management and self and family management of illness.  
Implications for Clinical Practice   
Our findings have several implications for clinical practice. The overall complexity 
of the clinical profiles of our sample, including high numbers of comorbidities, frequent 
healthcare utilization, and high rates of polypharmacy, likely reflect a low resource and 
medically vulnerable population treated in a safety-net system. Other studies have 
documented comparable findings noting complexities among comorbidities, healthcare 
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utilization, and polypharmacy in patients seeking care within safety-net health 
systems.25, 26 These findings suggest that pharmacogenetic testing in such systems may 
be particular challenging but may offer specific benefits. For example, testing may tax 
the financial resources of such safety-net health systems but might show important long-
term benefits by decreasing healthcare utilization related to adverse medication effects 
or non-response.  
The complexity of the clinical profiles of populations offered pharmacogenetic 
testing, however, must be considered in its implementation. With the extensive 
healthcare utilization and polypharmacy, frontline providers must be attuned to ever 
changing medication regimens across multiple care transitions and assess for potential 
drug-drug interactions that may lead to adverse drug effects or medication non-
response. For example, strategies such as the U.S. Food and Drug Administration step-
wise approach to prevent drug-drug interactions could be integrated in clinical practice to 
aid in preventing cytochrome P450 drug interactions.27 This approach includes taking a 
comprehensive medication history, identifying high risk patients, using available drug 
interaction references, and consulting pharmacists/drug information specialists.  
 Finally, because patients seek care in multiple outpatient settings such as 
primary care, specialty care, and emergency departments, availability of 
pharmacogenetic test results should be readily available across all care settings. As a 
result, having an infrastructure (i.e., meaningful use of electronic medical record, clinical 
decision support) will be essential in supporting the availability and use of 
pharmacogenetic test results.28, 29 Given the average length of time (14.5 years) that 
patients within this sample have sought care at the safety-net health system, it is likely 
that these patients will continue to seek care within this system. Therefore, the 
availability of the patient’s pharmacogenetic information could also be useful in the future 
when selecting and dosing other medications (i.e., metoprolol) or drug classes (i.e., 
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selective serotonin reuptake inhibitors [SSRIs]) metabolized by the CYP2D6 enzyme. 
Furthermore, provider education on available pharmacogenetic tests available, when to 
order them, and interpretation and communication of test results should be widespread 
across settings and disciplines (i.e., physicians, pharmacists, nurses).28  
Limitations 
 The findings should be interpreted in light of several study limitations. This was a 
secondary analysis of data from a small sample and only three clinical profile factors 
(comorbidities, healthcare utilization, and medication regimen) were evaluated. Although 
we used random selection of records to increase generalizability, the findings can only 
be generalized to populations prescribed pharmacogenetically actionable opioids in a 
safety-net health system and thus further research is needed to validate our findings in 
other populations. Additionally, while the data sources used were comprehensive and 
provided important clinical and administrative information, it was difficult to confirm the 
accuracy of the documentation (i.e., ICD-9 codes), determine whether data were missing 
(i.e., healthcare encounters not captured in data repositories), or if a patient was a non-
Indiana resident previously prescribed tramadol or codeine at a facility not captured by 
Indiana Network for Patient Care. 
Conclusion 
 We aimed to describe potential factors related to patients’ clinical profiles that 
could complicate the evaluation of outcomes associated with implementation of 
pharmacogenetic testing in patients prescribed pharmacogenetically actionable opioids. 
The findings indicated that patients prescribed these medications generally have 
complex medical histories, extensive healthcare utilization, and are concurrently 
exposed to numerous medications over a six month period of time. Consequently, these 
findings underscore the importance of multi-drug, multi-gene approaches to 
implementation of pharmacogenetic testing. Moreover, these factors have the potential 
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to confound the outcomes of pharmacogenetic testing; therefore, future research and 
clinical implementation initiatives of this testing to guide opioid therapies must control or 
account for patients’ comorbidities, healthcare utilization, and polypharmacy. 
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Table 4-1. 
Sample Characteristics & Comorbidities  
(n = 30) 
Gender n (%) 
Male 14 (46.7) 
Female 16 (53.3) 
Race  
White 18 (60.0) 
Black 11 (36.7) 
Biracial 1 (3.3) 
Comorbidities   
Non-pain diagnoses  
Hypertension 19 (63.3) 
Depression 15 (50.0) 
Dyslipidemia 13 (43.3) 
Diabetes 9 (30.0) 
Gastrointestinal Reflux 7 (23.3) 
Thyroid Disease 4 (13.3) 
Hepatitis 4 (13.3) 
Anxiety 3 (10.0) 
Atherosclerosis 2 (6.7) 
Asthma 2 (6.7) 
COPD 2 (6.7) 
Pain diagnoses  
Joint pain/osteoarthritis 19 (63.3) 
Back pain/lumbago 12 (40.0) 
Neuralgia/neuropathies 7 (23.3) 
Fibromyalgia 5 (16.7) 
Abdominal pain 5 (16.7) 
Cervicalgia 4 (13.3) 
Carpal Tunnel Syndrome 4 (13.3) 
Rheumatoid Arthritis 2 (6.7) 
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Figure 4-1. Figure shows total number of documented concurrent diagnoses for both 
non-pain and pain-related conditions for each of the 30 patients. Each bar represents an 
individual patient, as well as reflects their number of pain and non-pain conditions 
identified in Table 4-1. All patients had at least 2 or more documented comorbidities. 
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Table 4-2. 
Healthcare Utilization by Outpatient Clinic Type Over 6 Months Following New Prescription of a Pharmacogenetically Actionable 
Opioid 
 Mean # of visits  
(range) 
# of Visits by Patient [n (%)] 
0 1 2 3 4 5 6 ≥7 
Primary Care          
All visits 3.7 (1-8) --- 2 (6.7) 6 (20) 9 (30) 5 (16.7) 2 (6.7) 4 (13.3) 2 (6.6) 
Pain-related visits 1.8 (0-6) 7 (23.3) 8 (26.7) 5 (16.7) 5 (16.7) 4 (13.3) --- 1 (3.3) --- 
Specialty Clinic          
All visits 2.7 (0-10) 6 (20) 9 (30) 2 (6.7) 4 (13.3) 1 (3.3) 2 (6.7) 2 (6.7) 4 (13.3) 
Pain-related visits 0.7 (0-4) 16 (53.3) 10 (33.3) 3 (10) --- 1 (3.3) --- --- --- 
Emergency Dept.          
All visits 0.5 (0-10) 26 (86.7) 2 (6.7) 1 (3.3) --- --- --- --- 1 (3.3) 
Pain-related visits 0.4 (0-8) 26 (86.7) 2 (6.7) 1 (3.3) --- --- --- --- 1 (3.3) 
Total Clinic Visits          
All visits 6.9 (1-21) --- 2 (6.7) 1 (3.3) 2 (6.7) 4 (13.3) 2 (6.7) 7 (23.3) 12 (40) 
Pain-related visits 3.0 (0-13) 5 (16.7) 6 (20) 6 (20) 3 (10) 3 (10) 2 (6.7) 2 (6.7) 3 (9.9) 
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Table 4-3. 
Summary of the Type of Medications Prescribed  
Medication Type n (%) of Patients 
 Prescribed Medication^  
Mean # (range) of Medications 
per Patient*  
Total medications 30 (100) 10.0 (2-24) 
   
Pain medications 30 (100) 3.0 (1-8) 
PGxA opioid 30 (100) 1.0 (1-1) 
Additional opioids 13 (43.3) 1.5 (1-3) 
Anti-inflammatory 14 (46.7) 1.6 (1-3) 
Acetaminophen֍ 2 (6.6) 1.0 (1-1) 
Muscle Relaxant 6 (20) 1.0 (1-1) 
Anticonvulsant 7 (23.3) 1.0 (1-1) 
Other Adjuvant 5 (16.7) 1.0 (1-1) 
   
Cardiac medications 23 (76.7) 2.9 (1-7) 
   
Psychiatric medications 18 (60) 1.7 (1-3) 
   
GI medications 11 (36.7) 1.4 (1-2) 
   
Anti-infective medications 10 (30) 1.9 (1-5) 
   
Endocrine medications 8 (26.7) 1.6 (1-3) 
   
Respiratory medications 4 (13.3) 1.5 (1-2) 
   
Other medications 21 (70) 2.7 (1-8) 
^ Number of patients prescribed at least 1 medication per category. 
* Total medications (mean & range) for those patients prescribed at least 1 medication 
per category.  
֍ Numbers do not include acetaminophen as a combination with another medication 
(e.g., hydrocodone/acetaminophen).  
PGxA = pharmacogenetically actionable 
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Figure 4-2. Figure shows total number of documented medications, including 
pharmacogenetically actionable or other medications (horizontal axis). Each bar 
represents a patient (vertical axis). All patients had at least 2 medications which one was 
the pharmacogenetically actionable opioid (codeine or tramadol).  
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Table 4-4. 
Cytochrome P450 2D6 Drug-Drug Interactions & Clinical Interpretations 
Patient 
ID 
CYP2D6 
Diplotype 
CYP2D6 
Genotype 
Activity 
Score 
CYP2D6 DDIs Final 
CYP2D6 
Activity 
Score 
CYP2D6 
Drug 
Metabolizing 
Phenotype 
Clinical Interpretation 
07 *1/*41 
 
1.5 
 
Diphenhydramine1 – tramadol 0 PM Tramadol: Avoid medication due 
to lack of efficacy. 
Metoprolol: Be alert to adverse 
drug effects (e.g., bradycardia, 
cold extremities). 
Fluoxetine1 – metoprolol 
Diphenhydramine1 – metoprolol 
       
11 *2/*5 1 Diphenhydramine1 – tramadol 0 PM Tramadol: Avoid medication due 
to lack of efficacy. 
       
16 *1/*5 1 Fluoxetine1 – tramadol 0 PM Tramadol: Avoid medication due 
to lack of efficacy. 
       
19 *1/*4 1 Bupropion1 – codeine 0 PM Codeine: Avoid medication due to 
lack of efficacy. 
       
23 *1/*4 1 Duloxetine2 – tramadol 0.5 IM Tramadol: Avoid medication due 
to lack of efficacy. 
Metoprolol: Be alert to adverse 
drug effects (e.g., bradycardia, 
cold extremities). 
Duloxetine2 – metoprolol 
DDI: Drug-drug interaction; PM = Poor Metabolizer; IM = Intermediate Metabolizer 
1 CYP2D6 strong inhibitor: Final CYP2D6 Activity Score = 0. 
2 CYP2D6 moderate inhibitor: multiply CYP2D6 Genotype Activity Score by 0.5 to determine Final CYP2D6 Activity Score. 
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CHAPTER 5 
 The purpose of this dissertation was to advance the sciences of nursing, pain 
management, and pharmacogenomics through the development of a typology of 
common patterns of medication exposure to known pharmacogenetically actionable 
opioids. The dissertation results will be disseminated in three manuscripts. Manuscript 1 
(Chapter 2), which has been published in Nursing Outlook, is a review of 
pharmacogenomics in the nursing literature; Manuscript 2 (Chapter 3) is a presentation 
of the final typology; and Manuscript 3 (Chapter 4) is a discussion of contextual factors 
to consider when assessing and documenting benefits of pharmacogenetic testing in 
guiding opioid therapies. This chapter synthesizes key findings from all three 
manuscripts, the strengths and limitations of the study, and recommendations for future 
research. 
Synthesis of Key Findings 
 The first key finding was the need for nurses to more fully embrace the 
burgeoning field of pharmacogenomics. The nursing literature highlights the implications 
of pharmacogenetic testing for clinical practice in a variety of populations, including 
individuals seeking care for pain, cardiovascular disease, or psychiatric conditions. 
However, reports of evidence-based clinical practice guidelines for pharmacogenetic 
testing and empirical studies of pharmacogenomics are rare in the nursing literature. 
Some authors recommend: (a) enhanced evaluation of the effectiveness of genetic and 
genomic technologies, information, interventions, and outcomes; (b) future studies to 
explore the safety, efficacy, and effectiveness of pharmacogenetic testing and its impact 
on clinical and economic outcomes; and (c) the elucidation of nursing’s roles and 
responsibilities related to pharmacogenomics.1 This dissertation was intended to 
address the need for nurses to lead pharmacogenomic-related research.  
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 The second key finding was that exposure to pharmacogenetically active opioids 
is dynamic and complex. Previous pharmacogenomic research has over-simplified 
medication exposure and failed to capture its multifaceted nature.2 By using a person-
oriented approach, this dissertation documented some nuances of exposure to these 
medications. The final typology uncovered eight groups of patients who had one of five 
opioid prescription patterns (singular, episodic, switching, sustained, or multiplex) and 
one of three medical emphases for which care was being sought (pain, comorbidities, or 
both). The groups had varied patterns of medication exposure that unfolded over a six 
month period, confirming that medication exposure is a dynamic phenomenon that 
changes over time. Because the typology revealed meaningful subgroups of individuals 
with differing patterns of exposure to pharmacogenetically actionable opioid medications, 
it provides a more complex understanding of medication exposure than prior research.  
 The third key dissertation finding was that the medical emphasis of care provided 
a context for opioid exposure and was important in determining exposure patterns. The 
dissertation sample of 30 persons who were prescribed pharmacogenetically actionable 
opioids in primary care at the large safety-net health system had complex medical 
histories, extensive healthcare utilization, and were prescribed numerous medications. 
On average, the sample had five or more comorbidities, sought care approximately 
seven times, and had 10 different medications prescribed over the 6-month period of 
time. In addition, five had potential drug interactions that could affect their CYP2D6 drug 
metabolizing status. These findings indicate for patients with extensive medical histories, 
complicated healthcare utilization patterns, and complex medication regimens, multiple 
factors will need to be considered when assessing and documenting the benefits of 
implementing pharmacogenetic testing to guide opioid therapies. 
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Strengths of the Dissertation 
 This dissertation begins to address important limitations in previous research 
including oversimplified measures of medication exposure and lack of consideration of 
contextual factors likely to influence the implementation of pharmacogenetic testing. To 
my knowledge, this study is the first to employ a qualitative, person-oriented approach to 
explore patterns of medication exposure with data coming from existing clinical and 
administrative data repositories. This approach was an alternative to the variable-
oriented approach and yielded a new typology of subgroups. The identification of the 
eight subgroups, clustered on relevant characteristics of medication exposure, captured 
the complex nature of exposure to pharmacogenetically actionable opioids and 
accounted for the context in which the exposure to these medications occurred. 
 These findings contribute new information to the existing sciences of nursing, 
pain management, and pharmacogenomics. The dissertation manuscripts will add to 
nursing and healthcare literature by highlighting multiple factors that can influence the 
use of pharmacogenetic testing in the management of pain and other comorbid 
conditions in individuals prescribed pharmacogenetically actionable opioids. The 
dissemination of this work will advance our understanding of patients who have complex 
medication exposure patterns with numerous comorbidities, concomitant medications 
and multiple healthcare encounters.  
Another strength of this dissertation lies in its implications for nursing practice. 
These findings underscore that it is important for nurses to routinely monitor the 
medication responses of patients who are prescribed pharmacogenetically actionable 
opioids and to assess for factors that can impede their optimal analgesic effects, such as 
drug interactions that can affect CYP2D6 drug metabolizing activity. Furthermore, nurses 
should be aware of the multidimensional and complex patterns of medication exposure 
to pharmacogenetically actionable opioids and the context in which the exposure occurs.  
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This awareness can inform the development of personalized strategies to promote self-
management behaviors. Tools and strategies for medication management that are 
tailored to the complex clinical profiles of patients and the context in which their care is 
embedded may be more likely to promote optimal pain management outcomes and alert 
patients and providers to potential medication-related problems. For example, the 
Singular/Pain subgroup revealed in these findings may benefit from a one-time 
medication educational intervention about pharmacogenetic testing whereas the 
Multiplex/Both or Episodic/Both subgroups may require a more in-depth and sustained 
intervention, such as personalized health coaching, to promote self-management of pain 
and other comorbid conditions. 
Limitations of the Dissertation 
 The conclusions of this dissertation need to be interpreted in light of some 
limitations. While this qualitative, person-oriented approach provided a way to identify 
patterns common to small sets of cases and to describe how medication exposure 
unfolds over time, the approach does not allow for causative inferences such as how 
particular factors, such as type of pain or number of comorbidities, influence medication 
exposure, nor does it allow for conclusions about the frequency with which patients 
would fall into each group.  
Because the data were drawn from one group of patients treated in one 
healthcare system, the findings may not generalize beyond individuals who are 
prescribed codeine or tramadol in the primary care setting at a safety-net healthcare 
system. Furthermore, the retrospective nature and use of existing electronic health 
records make it difficult to confirm the accuracy of the documentation and determine 
whether certain data may have been missing. Although electronic health records provide 
important clinical and administrative information, these sources lack information on 
patient perspectives.3 For example, data elements related to the intensity, duration, 
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distress, and quality of an individual’s pain, along with their level of functioning, are not 
consistently documented or not captured within the electronic health record. Therefore, it 
was not possible to capture patient perspectives related to their pain and response to the 
opioid medication.  
Summary of Recommendations for Future Research 
 Several recommendations for future research stem from the findings of this 
dissertation. First, the subgroups within the existing typology could be used as a sample 
descriptor variable to ensure equivalence of randomization when comparing 
pharmacogenetic implementation to usual care. Using the subgroups as a sample 
descriptor variable allows for capturing an interaction of patterns between medication 
prescriptions and medical emphasis of care, which is more comprehensive than using 
individual variables such as age, diagnosis, or other clinical factors. Without assessing 
or accounting for the patterns identified through the typology, benefits of testing may not 
be as readily seen in subgroups with more complex patterns, such as Multiplex/Both or 
Episodic/Both groups, compared to the subgroups with more simple patterns such as the 
Singular/Pain group. Thus, comparing randomized groups on typology subgroup may 
provide important information about whether randomized groups are equivalent.  
Second, further development and validation of the typology using larger and 
more diverse samples drawn from a variety of healthcare settings is needed. Future 
research done prospectively could additionally capture the important information on 
symptom experience and functioning that was missing in this retrospective review. Such 
information could add depth to the existing typology. With a more developed typology, 
researchers could evaluate to what extent group membership may be related to 
particular clinical or economic outcomes related to the use of pharmacogenetic testing. 
For example, a more advanced typology could lead to identification of high-risk groups 
that may benefit from interventions related to medication management and inform the 
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development of tailored interventions for individuals prescribed pharmacogenetically 
actionable opioids. Multi-component interventions that include pharmacogenetic testing 
with additional components such as medication therapy management or care 
coordination could have a greater impact on improving clinical and economic 
outcomes.4, 5  
 Third, with further development and validation, the typology could aid in the 
development of more nuanced medication exposure measures that could then be used 
in studies evaluating clinical or economic outcomes of pharmacogenetic testing. Failing 
to account for medication changes over time can lead to exposure misclassification and 
measurement error.6 For example, future medication exposure measures must go 
beyond dichotomous measures and capture the length and pattern of exposure to a 
pharmacogenetically actionable opioid such as singular, episodic, sustained, switching, 
or multiplex exposure. Advancing science in this area will depend on further 
development of research strategies that can capture the heterogeneity of patients who 
are prescribed pharmacogenetically actionable opioids and the patterns of medical care 
in which the exposure occurs. 
Conclusions 
 This dissertation aids in understanding the complexity of medication exposure 
and contextual factors in individuals who were seen in primary care and prescribed a 
pharmacogenetically actionable opioid. The typology consisted of eight subgroups who 
shared common patterns of medication exposure. These findings can aid in addressing 
challenges related to the implementation of pharmacogenetic testing in clinical practice 
by indicating the need for future studies to develop measures of medication exposure 
that capture its dynamic nature and interventions to promote optimal implementation of 
pharmacogenetic testing based on variations in exposure patterns. These initiatives 
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could provide the foundation for the development of personalized health care strategies 
to improve pain management outcomes.   
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